



UNIVERSITY OF LEEDS

This is a repository copy of *Advances in understanding and in multi-disciplinary methodology used to assess lipid regulation of signalling cascades from the cancer cell plasma membrane*.

White Rose Research Online URL for this paper:
<https://eprints.whiterose.ac.uk/171433/>

Version: Accepted Version

Article:

Soteriou, C, Kalli, AC orcid.org/0000-0001-7156-9403, Connell, SD orcid.org/0000-0003-2500-5724 et al. (2 more authors) (2021) *Advances in understanding and in multi-disciplinary methodology used to assess lipid regulation of signalling cascades from the cancer cell plasma membrane*. *Progress in Lipid Research*, 81. 101080. ISSN 0163-7827

<https://doi.org/10.1016/j.plipres.2020.101080>

© 2021 Elsevier Ltd. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

1 ***Title page***

2 **Long Title**

3 Advances in understanding and in multi-disciplinary methodology used to assess lipid
4 regulation of signalling cascades from the cancer cell plasma membrane

5 **Running title**

6 Membrane methods in cancer

7 **Author list**

8 Soteriou C^{1,2,3}, Kalli AC², Connell SD³, Tyler All¹, Thorne JL^{1,*}

9 **Affiliations**

10 ¹School of Food Science and Nutrition, University of Leeds, Leeds, LS29JT, UK

11 ²Leeds Institute of Cardiovascular and Metabolic Medicine and Astbury Centre for
12 Structural Molecular Biology, University of Leeds, Leeds, UK.

13 ³Molecular and Nanoscale Physics Group, School of Physics and Astronomy, University
14 of Leeds, Leeds, LS2 9JT, UK.

15 *corresponding author j.l.thorne@leeds.ac.uk

16 **Key words**

17 Cancer, Membrane Lipids, Methodology, Signalling

18 **Conflict of interest statement**

19 The authors have no conflict of interest to declare

20

21

22 **Abstract**

23 The lipid bilayer is a functional component of cells, forming a stable platform for the
24 initiation of key biological processes, including cell signalling. There are distinct changes
25 in the lipid composition of cell membranes during oncogenic transformation resulting
26 in aberrant activation and inactivation of signalling transduction pathways. Studying
27 the role of the cell membrane in cell signalling is challenging, since techniques are often
28 limited to by timescale, resolution, sensitivity, and averaging. To overcome these
29 limitations, combining 'computational', 'wet-lab' and 'semi-dry' approaches offers the
30 best opportunity to resolving complex biological processes involved in membrane
31 organisation. In this review, we highlight analytical tools that have been applied for the
32 study of cell signalling initiation from the cancer cell membranes through
33 computational microscopy, biological assays, and membrane biophysics. The cancer
34 therapeutic potential of extracellular membrane-modulating agents, such as
35 cholesterol-reducing agents is also discussed, as is the need for future collaborative
36 inter-disciplinary research for studying the role of the cell membrane and its
37 components in cancer therapy.

38 **1. Introduction**

39 It is now a century since the cell membrane was shown to be composed of lipids, and
40 recent advancements in 'computational', 'wet-lab' and 'semi-dry' methodologies have
41 suggested additional novel concepts for the membrane lipids, such as lipid phases,
42 lateral heterogeneity, membrane thickness, diffusion and flip-flop motion[1]. Figure 1
43 shows how various lipids contribute to membrane features. Concepts that are now
44 emerging from the literature suggest that lipids within the membrane are not only
45 central for modulating structural membrane organisation, but have key functional role
46 in membrane-mediated initiation of cell signalling cascades[2]. Observations that lipid
47 composition is altered in diseases such as cancer have led to studies identifying the
48 functional roles in cancer signalling cascades for these membrane lipids[3-6].
49 Furthermore the hypothesis that short-lived[7] dynamic transient assemblies of
50 cholesterol/SM/saturated lipid-rich domains exist in membranes[8] has been

51 functionally linked to various oncogenic processes such as cancer cell signalling[9, 10]
52 and multi-drug resistance (MDR) [11, 12]. As a result, the range of applications for
53 cancer lipidomic studies has rapidly expanded yielding an array of lipid-targeting cancer
54 therapeutics[13-17] and diagnostic tools [18, 19]. This review details the range of
55 disciplines needed to understand these biophysical drivers of membrane associated
56 cancer cell biology with the cancer cell biologist in mind, and explores the fields of
57 computational biology, molecular and cell biology and biophysics. Methodological
58 complications and complexity are discussed, as is how inter-disciplinary collaborations
59 bypass the disadvantages of using each method/discipline in isolation. A mixed method
60 approach to understanding these processes will accelerate progress in the search for
61 novel cancer preventive and therapeutic agents.

62 **2. The cell membranes of healthy and tumour cells**

63 The mammalian plasma membrane comprises of a mixture of lipids and proteins that
64 form outer and inner leaflets of an asymmetric bilayer[20-22] (Figure 2A). The inner
65 leaflet contains mostly phosphatidylserines (PS), phosphatidylethanolamines (PE), and
66 phosphatidylinositols (PIs) while phosphatidylcholines (PC) and sphingomyelins (SM)
67 predominate in the outer leaflet (Figure 2B). Functionally, these lipids species allow
68 compartmentalised functions. The outer leaflet is afforded mostly structural and
69 barrier roles, and provides a platform for sensing the extracellular environment, whilst
70 the inner leaflet contains lipids that participate in and regulate signalling pathways.

71 **2.1. The physical properties of membrane lipids and their role in tumorigenesis**

72 The plasma membrane is made up of phospholipids which have hydrophobic tails that
73 face each other, and hydrophilic heads that face the intra- and extra-cellular water-
74 based environments. These amphipathic properties force natural (spontaneous)
75 assembly into a bilayer, driven by the hydrophobic effect. This holds true in the plasma
76 membrane of biological systems or in artificial conditions; simple water/lipid mixtures
77 forming many self-assembled lyotropic liquid crystals, including liposomes. The self-
78 organisation of phospholipids in living plasma membranes forms a ~5 nm wide double
79 layer of lipids. In non-biological systems self-assembled lyotropic crystals can be

80 artificially synthesised ranging from a few <50 nm up to 100 μm . While most membrane
81 phospholipids rarely (once in several hours) flip between the two bilayer leaflets
82 (cholesterol and some other molecules are the exception to this rule and flip flop more
83 rapidly), they also move laterally within each leaflet. Lipids may diffuse laterally
84 (translational freedom), rotate, or have flexibility around bonds in the carbon backbone
85 (configurational freedom/order) (Figure 1).

86 Lipid flip-flop is slow compared to lateral diffusion and typically takes 10^9 times longer
87 to occur than it takes a lipid to laterally diffuse 50\AA [23]. Lipid flip-flop is enzymatically
88 regulated by flippases, floppases, and scramblases, all of which preserve an asymmetric
89 contribution of lipids in the two membrane leaflets for long periods[24]. Lipid
90 movement, lipid order and membrane fluidity are greatly affected by lipid composition
91 with cholesterol playing a crucial role. The hydrophobic nature of the lipid tails prevents
92 polar molecules from easily passing through the membrane into the cytoplasm, thus
93 precisely maintaining the concentration of solutes of the cytosol, intracellular
94 compartments and the extracellular fluid. Instead, import and export of polar
95 molecules, ions, essential nutrients and metabolic waste products, are exquisitely
96 controlled by specialised transmembrane proteins.

97 More than 30% of the mammalian proteome encodes transmembrane proteins,
98 indicating the importance of membrane function[25]. These are proteins that are
99 surrounded by the lipids of the membrane for their lifetime. Membrane proteins
100 include transporters (carriers) and channels (aqueous pores) which transport
101 molecules via passive transport or facilitated diffusion. ATP-binding cassette (ABC)
102 transporters, which include P-glycoprotein (P-gp) comprise the largest family of
103 membrane transporters and are clinically very important for drug resistance in cancer
104 cells[26]. Membrane receptors are central to normal and oncogenic signal transduction
105 and determine the behaviour and function of their target cell [27]. Overington *et al.*
106 showed that about 60% of drug targets are membrane proteins[28]. Some of the most
107 common cancer transmembrane proteins that are drug targets include the epidermal
108 growth factor receptor (EGFR)[29], vascular endothelial growth factor, (VEGF)[30] and
109 integrins[31].

110 The cellular adaptations that occur during tumorigenesis such as rapid cellular division
111 confer new membrane biophysical characteristics to the cells [6, 32, 33]. Membranes
112 delimit the cell space from its environment but also preserve the characteristics of
113 membrane-enclosed organelles (endoplasmic reticulum (ER), mitochondria, Golgi
114 apparatus) and the cytosol. Membranes are the immediate inter-cellular structures
115 connecting healthy and cancer cells and form a structural barrier between the cell
116 components and the microenvironment (e.g. other cells, matrix, growth factors, ions,
117 hormones, cytokines) and thus control the transmission of signals between the extra-
118 cellular environment to intracellular processes. While the structural features of
119 membranes were studied for decades, lipid structures and their functions are only now
120 emerging as therapeutic targets in oncogenesis (reviewed in [17, 22]). In cancer,
121 changes in cell membrane lipid composition, packing, and fluidity, are widespread[6,
122 34, 35] (Figure 2C) and are functionally and mechanistically linked to oncogenic
123 signalling[9, 10], metastasis[36, 37], angiogenesis[38, 39], drug resistance[11, 12], and
124 even cancer immune surveillance[40, 41]. Although the role of the immune system in
125 tumorigenesis is not the scope of this review, we direct the reader to reviews focusing
126 on the crosstalk between immune and cancer cells, mechanistically linked to cancer
127 immune surveillance (reviewed in [40, 41]). Immune cells, part of the tumour
128 microenvironment, are influenced by their own lipid compositions and were reported
129 to be regulated by lipid components. For example, compositional changes seen in
130 cancer (see section 2.2), such as PS exposure on the outer cancer membranes, allow
131 cancer cells to evade recognition and targeting by immune cells, like natural killer (NK
132 cells)[42]. Targeting lipid reprogramming in immune cells and their effect on tumour
133 cells is an emerging and additional field of research for lipid-targeted cancer
134 immunotherapy is attracting more interest over the years[41].

135 **2.2. Alterations of membrane lipid composition during tumorigenesis**

136 Lipidomic studies on primary tissue and cancer cell lines provided insights into the
137 alteration of membrane lipid composition in tumorigenesis. While primary cells retain
138 the morphology and function of the tissue of origin, they are not appropriate models
139 for studying lipidomic profiles in metastasis and multi-drug resistance. Models of

140 metastatic and MDR cell lines are in concordance and overcome primary cell
141 limitations. A systematic evaluation of lipid membrane composition in cancer was
142 performed and 29 papers were included in qualitative analysis. Our search
143 methodology is reported in Supplementary Tables, and our findings are summarised in
144 Figure 2D with full details of all lipid classes in every cancer/cell type we identified in all
145 29 papers of primary cell and cancer cell line studies. The lipid composition of cancer
146 cell plasma membrane varies with the type of cancer[17, 43, 44] as well as the severity
147 of the disease [45] and was shown to be associated with patient survival[45]. In breast
148 cancer, higher levels of PE lipids [45-47], PC-saturated fatty acid rich lipids[45-48], SM
149 lipids[45, 46], and of the lipid messengers, PIs [45-48], have been reported in
150 comparison to non-cancerous tissue (Figure 2D). An increase in PI lipids was also
151 observed in Ras-induced lymphoma cells[49]. In *Myc*-induced lymphoma cells PS, PE
152 and PI lipids were decreased and phosphatidylglycerol lipids increased compared to
153 normal cells [49]. Typically in healthy cells, PS lipids are asymmetrically localised in the
154 inner layer of the plasma membrane[50] and this asymmetry is maintained by
155 aminophospholipid translocases[51]. Loss of function of the protein machinery
156 responsible for maintaining membrane asymmetry[52] results in PS translocation to
157 the outer leaflet, a key stage in apoptosis. PS lipids move to the outer layer during
158 transformation to cancer[53-56] (Figure 2C) and is associated with worse cancer
159 outcomes[57]. This translocation has been found mediated by P-glycoprotein
160 (ACBB1/MDR1/P-gp) [58] and also activates the coagulation pathway which enhances
161 activity of pro-survival factors, again favouring oncogenesis[57, 59]. Similar findings
162 have been reported for PE lipids[52]. These observations allowed subsequent
163 mechanistic insight into the anti-cancer peptide Polybia-MP1; movement of both PS
164 and PE lipids to the outer leaflet in cancer cells enhanced membrane poration due to
165 the charged PS electrostatically attracting MP1, and the PE stabilising the formation of
166 large pores. [60].

167 During metastasis a change in biophysical properties of the plasma membrane is
168 required to allow the amoeboid like migration, extravasation, dissemination and
169 extravasation[34-36]. Alterations to the lipid content as measured by cell
170 polarisation[61], have been observed in cancer metastasis with increased SM and PE

171 concomitant with decreases in cholesterol in unpolarised cells during the relatively
172 early stage of metastasis of epithelial-to-mesenchymal transition (EMT)[62]. While
173 alterations in membrane lipid composition are cancer and disease stage specific, a
174 trend for metastatic[62, 63] and blood cancer cells[64] to have lower cholesterol and
175 MDR[4, 65, 66], greater membrane cholesterol has been observed in some situations
176 (Figure 2C). Gene ontology analysis revealed that the cholesterol biosynthetic pathway
177 is upregulated during acquisition of multi-drug resistance [67]. Wang *et al.* showed that
178 inhibiting the enzyme that synthesises polyunsaturated phospholipids
179 (lysophosphatidylcholine acyltransferase 3 [Lpcat3]) decreases membrane fluidity and
180 induces cholesterol biosynthesis[68]. Increase in cellular cholesterol content was
181 sufficient to independently enhance intestinal stem cell proliferation and
182 tumorigenesis *in vivo* and *ex vivo*[68].

183 Loss of bilayer asymmetry also stimulates aberrant and oncogenic cell signalling[69-
184 71]. Biophysical models of asymmetric membranes have indicated that formation of
185 signalling regulatory domains, which are expected to preferentially form in one leaflet
186 due to the asymmetric lipid composition, were actually suppressed by the asymmetric
187 opposing leaflet which lacked domains [72]. Scrambling of the leaflets, thus resulting in
188 symmetrical lipid layers, causes formation of cholesterol-rich domains that are
189 predictable based on the lipid composition of the bilayer [72]. The forces linking phase
190 behaviour in the opposing leaflets of a bilayer are not currently understood and
191 represent an important gap in the understanding[72].

192

193 Repressing cholesterol availability can promote metastasis in breast cancer[73].
194 Moreover, palmitoylation of the surface adhesion receptor stem cell marker CD44,
195 which facilitated its localisation to cholesterol-rich membrane domains, resulted in
196 limiting metastasis[37, 74]. These findings indicate that decrease in membrane fluidity
197 by localisation of the protein CD44 from low- to rich-cholesterol regions had an anti-
198 migratory effect.

199 2.3 Membrane cholesterol regulates membrane function

200 Cholesterol is an important component of the membrane comprising up to 30-40% of
201 the membrane lipids in specialised cells[20, 75]. Cholesterol is also a main component
202 of specialised membrane domains. The increase in cholesterol in some cancer cells [65,
203 68, 76, 77], is linked to elevated levels of cholesterol-rich membrane domains[78, 79]
204 that are involved in oncogenic signalling[78, 79]. These domains are a result of
205 preferential lipid/cholesterol interactions, which drive lateral heterogeneity in
206 membranes and the formation of distinct lipid phases, the liquid ordered (L_o) and liquid
207 disordered (L_d) phases[80] (see section 2.4). In 1997 cholesterol-rich domains were first
208 defined as 10-200nm dynamic-ordered transient assemblies enriched in cholesterol
209 and sphingolipids or saturated lipids, and were defined as lipid rafts[8]. Even-though
210 the lipids of lipid raft domains are more ordered, L_o phases and lipid rafts are not
211 interchangeable terms.

212 Alterations in cholesterol concentration results in an array of biophysical changes that
213 affect the behaviour of cancer cells. For example, cholesterol-driven lateral membrane
214 heterogeneity is linked to membrane protein pump opening and closing, critically
215 diminishing the cells' ability to maintain gradients. As an example, the ABC transporters
216 are organised into distinct cholesterol-rich domains[81], and are surrounded by a
217 region enriched with cholesterol and PC lipids[82]. This local environment creates
218 multiple non-specific interactions between the lipids and the transporter proteins that
219 impact conformation and its efflux capacity[11]. Mechanosensitive ion channels such
220 as PIEZO1, which has been linked to several cancers[83], is also functionally dependent
221 on membrane lateral organisation and the presence of cholesterol-rich domains[84].

222 Increase in membrane rigidity and thickness driven by increased saturated lipids with
223 long fatty acyl chains and elevated cholesterol, reduces passive diffusion and
224 permeability to amphipathic and hydrophilic drugs (Figure 1)[12, 26, 85]. Increase in
225 cholesterol concentration results in increased hydrogen bonding between headgroups
226 of lipids and cholesterol[86] and subsequently to a tighter and thicker membrane with
227 a reduced number of empty spaces, thus creating a greater distance and a greater
228 barrier in the membrane for the influx of drugs[12, 26, 85]. MDR breast[65],

229 leukemic[4] and ovarian[66] cancers have all been found to contain significantly greater
230 cholesterol content, and higher membrane lipid order[87] than their drug-sensitive
231 counterparts. Peetla *et al.* suggested that this cholesterol-driven increase in membrane
232 rigidity results in the chemotherapy drug being trapped in the membrane[65] (Figure
233 1) and Rivel *et al.* even provided evidence that membrane permeability to cisplatin was
234 proportional to cholesterol concentration [88, 89]. Depleting membrane cholesterol
235 through cholesterol-reducing agents leads to decreased P-gp activity[12] and P-gp
236 transport function[85], indicating intra-cellular concentration of the many anti-cancer
237 therapeutic substrates of this pump is at least partly dependent on membrane
238 cholesterol concentration.

239 Cholesterol is a modulator of lateral mobility and diffusion of membrane lipids and was
240 shown to linearly decrease, or increase with increase or decrease of cholesterol
241 concentration, respectively[90]. Similar effects of cholesterol concentration were also
242 observed for other membrane components, such as membrane proteins
243 (Glycosylphosphatidylinositol-linked and native major histocompatibility complex class
244 III-I-E^k)[91]. Lateral diffusion is an important property for membrane-associated
245 proteins and has been suggested to impact the clustering of lipids essential for binding
246 specific proteins and thus increasing their binding affinity. For example, the FERM
247 domain of the ezrin receptor, which is responsible for binding of the protein to the
248 bilayer, was suggested to slow down the lateral diffusion of phosphatidylinositol 4,5
249 bisphosphate (PI(4,5)P₂)[92]. This resulted in clustering of PI(4,5)P₂ that increased its
250 local density around the protein and resulted in greater binding affinity to the
251 membrane compared to the absence of protein[92].

252 Cholesterol-rich domains in cancer cell membranes have been suggested to act as hot-
253 spots for cancer cell signalling cascades, through the physical segregation of some
254 proteins in these domains that results in modulation of their accessibility to their target
255 molecules[93, 94]. It is suggested that various proteins associate with rafts[95-97] (and
256 are “raftophilic”) or are otherwise excluded from lipid raft domains[98]. The physical
257 co-localisation of some proteins in these domains might bring them in close proximity
258 favouring their interaction and enhancing the sensitivity to cellular signalling

259 cascades[99]. Apart from protein-protein interactions, lipid-protein interactions were
260 shown to facilitate the over expression of some membrane-receptors (such as
261 EGFR[100], CD44[37]) and to mediate survival of oncogenic peripheral proteins, such
262 as Akt[101].

263 2.4. The biophysics of lateral heterogeneity in cancer cells

264 The lipid raft hypothesis has been a controversial topic in modern membrane biology
265 for many years and only recently, following improvements in methodologies with the
266 required temporal and spatial resolution (Figure 3), stronger direct evidence of lipid
267 rafts has been obtained in live cells[102, 103]. Although controversial, the self-
268 organising capability of eukaryotic membranes is undeniable[80] and there is therefore
269 still a lot to be discovered and understood about lipid rafts and their function in
270 tumorigenesis using appropriate techniques. Lipid rafts likely play crucial roles in
271 cellular bioactivity including membrane-recruitment of lipids and proteins, and
272 importantly in oncogenesis, cell signalling initiation[8].

273 The plasma membrane is home to more than 1000 different lipid species[104], which
274 participate in lipid-lipid interactions and drive lateral heterogeneity and phase
275 separation[1, 105, 106]. Cholesterol preferentially interacts with saturated (rather than
276 unsaturated) lipids[107, 108] since saturated chains permit maximal lipid-cholesterol
277 interaction, via Van der Waals attraction, whereas the “kinks” in unsaturated lipid tails
278 form from double bonds, making close packing difficult. As a result of this binding,
279 cholesterol’s rigid ring induces a high degree of saturated lipid acyl chain
280 conformational order, drives phase separation, and subsequently makes the
281 cholesterol/saturated fat/sphingolipid-rich domains more packed and highly
282 ordered[109]. Phase separation is observed in ternary mixtures of model membranes,
283 where preferential lipid-lipid and lipid-cholesterol interactions occur. These
284 preferential interactions result in lateral heterogeneity and domain formation of liquid-
285 ordered (L_o) rich domains (cholesterol abundant) and liquid-disordered (L_d) rich
286 domains (cholesterol scarce)[20]. In the L_o phase, lipids with a high melting
287 temperature (T_m) (saturated lipids) cluster with themselves and/or cholesterol and are
288 separated by clusters of low melting temperature (T_m) lipids (unsaturated lipids) that

289 cluster on their own. Cholesterol reduces the conformational freedom of the lipid
290 chains resulting in a thicker and more rigid bilayer in the L_o phase compared to the more
291 fluid L_d phase [110, 111]. The L_o phase closely resembles the gel phase for having high
292 molecular ordering while being laterally highly mobile, two to three times slower like
293 the L_d phase. The L_o and L_d fluid phases co-exist in the membranes under suitable
294 conditions (lipid content, temperature, pressure), which are met in biological
295 membranes. These observations of lateral heterogeneity at the sub-micron level were
296 made through biomimetic model membrane techniques and led to the generation of
297 the lipid raft hypothesis[8].

298 Fluorescence based-methodologies have provided convincing evidence that lipid rafts
299 are enriched in cancer [78, 79, 108, 112, 113]. Li *et al.* showed that several cancer cell
300 lines contain more L_o membrane domains and are more sensitive to cholesterol
301 depletion than their normal counterparts[78]. Hyper-sensitivity of cancer cells to
302 cholesterol depletion was corroborated in colon cancer cell cultures, when inhibitors
303 of cholesterol biosynthesis, such as statins, slowed proliferation and enhanced
304 apoptosis[78]. A number of studies show that L_o phases comprise a biologically
305 meaningful portion of the plasma membrane in several cell types [114, 115] including
306 HeLa cells derived from the cervical cancer that killed Henrietta Lacks [116, 117].
307 Levental *et al.* studied the role of palmitoylation in regulating integral protein affinity
308 for L_o domains[118]. This group suggested that approximately 30% of plasma
309 membrane proteins were clustered in L_o domains of giant plasma membrane
310 vesicles[118]. On the other hand, methodologies involving membrane-order-sensitive
311 dyes and fluorescence lifetime shifts on intact cells, suggested the existence of sub-
312 resolution mixture of 76% ordered and 24% disordered lipid domains suggesting that
313 L_o domains might dominate the plasma membrane. These observations suggest that
314 while 76% of actual biological membrane is in L_o phase, only 33% of membrane proteins
315 are clustered in L_o domains. Extrapolation of these data indicate that 66% of all
316 membrane proteins are restricted to the 30% of the membrane comprising the L_d
317 phase. While many studies argue about the biological importance of the L_o phase for
318 membrane proteins, this observation indicates that most proteins would rather be
319 overcrowded into the small amount of L_d. Furthermore, this perhaps indicates

320 inconsistencies between different methodologies and that we do not really understand
321 the biological importance of the membrane properties and its domains, especially at
322 the stage of disease. Decades of research with model membranes allowed researchers
323 to understand the physical chemistry behind domain formation. However, few studies
324 were able to provide direct evidence that the living mammalian plasma membrane can
325 self-organise. Giant plasma membrane vesicles (GPMVs) provide an intermediate
326 biological system as they are isolated from live cells [105], preserving the lipid and
327 protein diversity and complexity and the natural properties of the living cell plasma
328 membrane[105, 119], but maintain the resilience of model membranes[105, 120, 121].
329 As a result, these natural membranes allow observation of biological plasma membrane
330 phenomena, such as phase separation. Very recently, direct evidence of nanodomains
331 in biomimetic and biological membranes[102, 103] has been found adding further
332 support to the hypothesis that lateral heterogeneity has vital physiological significance
333 [122]. Recent methodological developments have provided direct evidence that lateral
334 heterogeneity exists in cell membranes, meaning prior debate was most likely
335 stimulated by limitations of previous methodologies unable to resolve the dynamic and
336 nanoscopic nature of membrane domains and membrane properties. Therefore focus
337 on more appropriate interdisciplinary methods should be given to understand the
338 biological significance of rafts in cancer[122].

339 **3. Molecular and Cell Biology**

340 **3.1. From detergents to dyes**

341 Non-ionic detergents played a significant role for decades in the study of the plasma
342 membrane and the proteins that reside within it. Detergent-based methods were some
343 of the first methods to suggest membrane domains organise signals from the plasma
344 membrane. Separating membrane proteins from the hydrophobic lipids in which they
345 are embedded has historically been achieved through exploiting the hydrophobic
346 properties of lipids. Highly compartmentalised membrane regions are separable using
347 non-ionic detergents such as Triton X-100 or CHAPS at low temperatures[9, 123, 124].
348 These detergent-based methods have been widely used for decades to separate

349 detergent-resistant membrane fractions with similar components to rafts being rich in
350 cholesterol, associated protein markers and sphingolipids[100, 125-127]. However,
351 detergent based methods have many limitations for representing L_o phases in cells.
352 Detergent based methods require low temperatures that render the native membrane
353 asymmetry undetectable and that may independently induce phase changes[128, 129].
354 The composition of membrane protein partitioning into detergent and non-detergent
355 regions was suggested to be depended on the type concentration of detergent used
356 for isolation[130]. Detergent-resistant membranes (DRMs) have been observed as
357 artefacts resulting from methods that fail to completely solubilise membranes [122,
358 129-131] and that could be a result of leaflet-specific detergent sensitivity[132].
359 Detergent-based techniques are still used, and they do provide valuable information
360 about protein-lipid interactions, but methodological effects driven by detergents must
361 be controlled and accounted for[129]. Detergent-based techniques are still commonly
362 employed as they are a simple, fast, and inexpensive method to observe if the
363 membrane has the propensity to form domains and provide estimates of protein-lipid
364 interactions. Throughout the years, the caveats arising from the use of these
365 techniques has become well-known and a shift towards the use of fluorescent dyes has
366 occurred.

367 Fluorescent probes allow quantitative analysis of cholesterol concentration, lipid/lipid
368 and lipid/protein molecular aggregation, compartmentalisation, and lateral diffusion.
369 Fluorescent probes are highly sensitive and can be applied in simple model membranes
370 to complex cellular systems alone or in combination with techniques to achieve spatial
371 and/or temporal resolution. Environmentally sensitive fluorophores are affected by the
372 polarity of their native environments particularly by water penetration into the bilayer
373 and the dipolar relaxation effect [133, 134]and so are good probes for the study of lipid
374 packing and membrane fluidity. Lipids contributing to L_o phases have less hydrated
375 headgroups and higher lipid order compared to L_d phases, since they use more
376 hydrogen bonds to bind together, leaving less available for binding to free water [135-
377 137]. Greater lipid order results in lower polarity meaning sufficiently sensitive probes
378 distinguish phase changes of their local environments. However, as with detergents,
379 dyes have limitations. Lipid labels may be bulky, hydrophobic, and reduce the affinity

380 for liquid ordered phases[122] leading to artefactual changes in lipid partitioning[138].
381 For example, fluorescence labelling of lipids normally found in L_o domains [138] with
382 the 3-HF probe, F2N8, were nearly impossible to be labelled in the L_o phase in coexisting
383 L_d/L_o bilayers, since the probe affected the properties of the unlabelled native lipids
384 [139]. Probe specificity for the different phases, with negligible flip-flop between the
385 two bilayer leaflets, is also an important consideration. In typical plasma membranes,
386 probes that label L_o should be specific to the high cholesterol, SM, and saturated lipid
387 regions of the outer bilayer, and therefore reveal bilayer asymmetry.

388 The potentiometric styryl dye di-4-ANEPPDHQ was first developed and applied in
389 neuronal studies as a fluorescent sensor of transmembrane potential[140]. As di-4-
390 ANEPPDHQ's emission spectrum is partially related to cholesterol concentration it has
391 also been used to visualise phase separation in cell membranes[141] (Figure 4). Di-4-
392 ANEPPDHQ is excited at 488nm and shifts its emission from a peak at about 560 nm
393 (green) in the L_o phase, to 620nm (red) in the L_d phase[142], and dissociation of lipid
394 domains can be visualised in cholesterol depletion experiments[141]. This dye is unique
395 compared to other potentiometric dyes in that it has low cellular toxicity; it is water-
396 soluble, with a short rate of internalisation into the membrane[141]. Di-4-ANEPPDHQ
397 is non-fluorescent until bound to membranes and, it only shows slight fluorescence in
398 water, minimising background fluorescent influences. Study of membrane lipid
399 domains with di-4-ANEPPDHQ, has been previously performed using vesicles made of
400 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), egg n-palmitoyl-sphingomyelin
401 (PSM), DPPC and different cholesterol concentrations or in live cells through direct
402 addition to the culture medium[141, 143]. di-4-ANEPPDHQ's excitation and emission
403 spectra can be assessed with a spectrofluorometer and when combined with confocal
404 fluorescence microscopy provides detailed information on membrane structure and
405 colocalization with proteins that have themselves been tagged, with for example GFP
406 [143]. Di-4-ANEPPDHQ staining in live epithelial (HEK293) cells can also be combined
407 with fluorescence lifetime imaging (FLIM) to study increased order in the plasma
408 membrane and appears to be a robust tool for identifying membrane microdomain
409 formation and function in live cells[143].

410 Laurdan is another environmentally sensitive fluorophore that allows the study of lipid
411 packing and membrane fluidity[133, 134] (Figure 4). Laurdan is excited by UV and is
412 sensitive to lipid phase changes, emitting fluorescence at around 500nm (blue) when
413 the lipids are in the L_d phase and shifted at about 450nm (violet) when the lipids are
414 more packed and in the L_o phase[115, 142]. Importantly for the cell biologist, Laurdan
415 can be applied not just in model membranes, but also in live and fixed cells, and has
416 even been utilised in whole organisms (live zebrafish embryos) without affecting native
417 membrane properties[142]. Sanchez *et al.* used Laurdan with scanning fluorescence
418 correlation spectroscopy (FCS) (instead of single-point FCS) to study membrane
419 heterogeneity and membrane fluidity in intact live rabbit erythrocytes and Chinese
420 hamster ovary cells. This group observed generalized polarization (GP) fluctuations in
421 the cell membranes of live cells and proposed that these fluctuations represented the
422 existence of tightly packed micro-domains moving in a fluid background phase [115].
423 The GP quantitatively measures the emission shift of the dye and in this study gave a
424 high-GP, tightly packed L_o structures diffusing in a background of less packed lipids with
425 lower-GP[115]. Disadvantages of Laurdan however include phototoxicity towards live
426 cells caused by UV illumination[144] and low solubility of Laurdan in water. To address
427 this, C-Laurdan has been designed with a carboxymethyl group replacing a methyl
428 group (in the headgroup) and so shows improved solubility and provides brighter
429 fluorescence signals, thus improving its applicability to live cells[145]. Recently, Salinas
430 *et al.* combined C-Laurdan and di-4-ANEPPDHQ to reveal that the plasma membrane
431 might be a central mechanistic link between obesity and colorectal cancer[146].
432 AdipoRon, an inhibitor of the adipocyte secreted factor adiponectin, was observed to
433 reduce plasma membrane free cholesterol and rigidity resulting in suppression of
434 oncogenic Wnt signalling in colon cancer [146]. Wnt-receptor binding occurred
435 selectively in L_o membrane domains[147]. With the use of environment-sensitive
436 fluorescent probes the biophysical properties of membranes in live cells in relation to
437 tumorigenesis can be studied and provide insights to develop novel cancer membrane-
438 targeted therapies.

439 Detergents have been used to reveal crucial information regarding the biological
440 signalling functions of the plasma membrane, but the emergence of dyes has

441 exacerbated the limitations of detergents. Careful consideration as to which dye to use
442 should still be given, as some may influence lipid partitioning and others have been
443 further developed to improve utility in the study of live cells.

444 3.2. Antibodies

445 Hyperphosphorylation and expression of oncogenic proteins indicates enhanced cell
446 signalling initiation, usually synonymous with cancer hallmarks characteristics. Directly
447 detecting changes in protein levels and phosphorylation using antibodies remain
448 common methodologies to measure signalling initiation[148]. Immunoblotting and
449 immunofluorescence alone, and in combination with confocal microscopy or
450 immunoprecipitation, all utilise antibodies raised against the antigen of interest for
451 measuring activity of cell signalling pathways. These are well-established antibody-
452 based techniques that quantify and localise (coarsely) proteins and determine the
453 abundance and variety of post-translational modifications (PTMs)[149, 150]. Protein-
454 protein interactions that indicate signal transduction, can be detected using co-
455 immunoprecipitation[149] or with fluorescent methods such as FRET (described in
456 detail below).

457 Antibody-based techniques are widely used for studying signalling mechanisms that are
458 sensitive to changes in membrane lipid concentration and functions. A lot of the initial
459 evidence on cholesterol sensitivity of oncogenic protein expression and the role of
460 cholesterol-rich domains in localising some membrane and peripheral proteins has
461 been obtained through antibody-related techniques. In many cases, antibody-based
462 approaches were used in combination with detergent-based extractions and sucrose
463 gradient ultracentrifugation[151], or with non-detergent based biochemical raft
464 fractionation methods[126, 152] to separate “raft” and “non-raft” membrane
465 fractions. Adam *et al.* following detergent-based isolation of membrane fractions (by
466 sucrose gradient ultracentrifugation and detergent extraction with Triton) of prostate
467 cancer cells, used immunoblotting, immunoprecipitation and immunofluorescence to
468 show partitioning of oncogenic Akt in membrane domains[125]. Oncogenic Akt was
469 overrepresented in cholesterol-rich (raft) microdomains compared to wild type
470 Akt[125]. Depletion of cholesterol by methyl-beta-cyclodextrin (cholesterol-binding

471 agent) inhibited Akt signalling originating from raft domains and reduced oncogenic Akt
472 phosphorylation, leading to an overall decrease in cell survival signalling[125]. Similar
473 findings were observed by Chun-Li *et al.* with immunoblotting, immunofluorescence,
474 and confocal microscopy for detection of Akt, pro-apoptotic proteins, and raft markers
475 (Cholera toxin B subunit (CTB), filipin, monosialotetrahexosylganglioside (GM1)) in
476 prostate and breast cancer lines without the use of detergents[78]. CTB binds GM1
477 lipids that are concentrated in cholesterol-rich domains much like lipid rafts[153].
478 Membrane cholesterol depletion resulted in reduced expression of raft levels along
479 with down-regulation of Akt activity and upregulation of pro-apoptotic proteins (Bcl-
480 xL, caspase-3)[78]. Using a non-detergent based raft isolation (lysis of breast cancer
481 cells using a calcium and magnesium isotonic buffer and floatation in an OptiPrep
482 gradient), immunoblotting and immunoprecipitation, Irwin *et al.* showed that EGFR and
483 c-Src co-localised to raft membrane domains[100]. Co-localisation of EGFR and c-Src in
484 the membrane raft fraction was also observed when breast cancer cells were
485 immunostained with Alexa fluor labelled EGFR, c-Src and CTB antibodies[100]. Using
486 immunoprecipitation, immunoblotting and immunofluorescence. Donatello *et al.*
487 studied the role of cholesterol-rich domains in the promotion of breast cancer cell
488 migration[37]. Following both detergent and non-detergent-based extraction methods
489 of membrane domains from migrating and non-migrating breast cancer cells this group
490 suggested that in non-migrating conditions CD44 is mainly localised in raft fractions and
491 ezrin mainly localised in non-raft fractions[37]. Following the induction of migration,
492 CD44 is retained in non-raft fractions and coprecipitated strongly with ezrin[37].
493 Depleting cholesterol and subsequently disrupting rafts resulted in increased
494 coprecipitation and colocalisation of CD44/ezrin in the non-raft fractions during
495 migration[37]. This study using various antibody-based techniques suggested that raft
496 domains might be involved in the regulation of CD44-dependent breast cancer cell
497 migration[37]. Similar findings were observed by a recent study that showed less CD44
498 localisation into lipid rafts in highly metastatic hepatocellular carcinoma (HCC) cells
499 than normal liver cells[154]. Treatment of cholesterol promoted the formation of lipid
500 rafts, the translocation of CD44 into lipid rafts, decrease in CD44/ezrin interaction and
501 thus inhibition of migration and invasion[154]. These findings were confirmed in clinical

502 HCC tumour samples of patients with high or low serum cholesterol and in a mice liver
503 metastasis model with or without hypercholesterolemia[154]. *In vitro* and *in vivo* data
504 using a combination of antibody-based techniques such as immunoprecipitation,
505 immunofluorescence and immunoblotting as well as raft isolation techniques such as
506 detergent-based or fluorescent-based (with raft markers) were in agreement[154].

507 Antibody-based techniques have been and are still widely used for the study of
508 membrane properties and membrane associated signalling in cancer. While their
509 applications were originally attributed to molecular biology assays, their use has been
510 extended to biophysics and super resolution microscopy. In combination to
511 fluorescence-based applications antibody-based methods are powerful tools in
512 understanding the complexity of the plasma membrane and the lipid-lipid or protein-
513 lipid interaction in cancer membrane bioactivity.

514 3.3. Lipidomics

515 Lipidomics is the study of the structure and function of the lipidome, which includes
516 the complete set of lipids in a cell. It provides information about chain length,
517 headgroup chemistry and quantification of lipids and thus providing important
518 information on molecular mechanisms that characterise tumorigenesis[155].
519 Lipidomics has been used to provide insights into global membrane lipid composition
520 and dynamic changes during tumorigenesis, which emphasise the potential of lipid-
521 centric therapeutics in cancer[3]. Determining the membrane lipid composition of
522 cancer cells is critical in understanding the biological properties of tumours. Mass
523 spectrometry (MS) methodologies suggested specific lipid types to be markers for
524 cancer diagnosis. MS is a label free technique which can explore the lipid composition
525 of healthy cells/non-cancerous tissue compared to cancer cells/tissue.

526 Maciel *et al.* studied the lipid remodelling in human melanoma cells upon UVA
527 exposure using gas or liquid chromatography (GC or LC) coupled to MS. This study
528 observed an increase of monounsaturated fatty acids (MUFA), stearic acid (FA:18:0)
529 and PI lipids and a decrease of palmitic acid (FA16:0) and PC lipids following 24 hours
530 of irradiation[156]. Cifkova *et al.* used liquid chromatography in combination to

531 electrospray ionization mass spectrometry quantification to study the lipidomic
532 characterisation of breast cancer and the surrounding normal tissue of the same
533 patient[46]. Significant increases in PI, PE and PC lipids were observed in breast cancer
534 tissues compared to the normal tissue[46]. Conventional mass spectrometry methods
535 usually involve lipid extraction, separation by chromatography before mass
536 spectrometry detection. More recent applications have employed mass spectrometric
537 detection without the requirement for lipid extraction and separation, but using *in situ*
538 detection of membrane lipids, that maintains cell integrity[157]. He *et al.* used such
539 method to study the membrane lipid profiling of an epithelial breast cell line compared
540 to the lipid profiling of six different breast cancer cell lines linked to their metastatic
541 ability using matrix-assisted laser desorption/ionization (MALDI)-Fourier transform ion
542 cyclotron resonance mass spectroscopy[157]. This method is based on the circular
543 movement of charged particles in a strong magnetic field, named the cyclotron
544 movement of which its frequency directly depends on the mass-to-charge ratio of the
545 ions[158]. Alterations in the levels of lipids were associated with the types of the
546 different breast cancer cell lines[157]. In total, levels of eight membrane lipids were
547 found to differentiate the healthy cell line from the six breast cancer cell lines.
548 Furthermore 15 lipids were different between the six breast cancer cell line types[157].
549 Significant increase of monounsaturated lipids was also associated with the degree of
550 malignancy in the breast cancer cells[157]. Frisz *et al.* used a high-resolution chemical
551 imaging approach to detect sphingolipid-enriched plasma membrane domains in
552 mouse fibroblasts[159]. Sphingolipids within the plasma membrane of mouse
553 fibroblasts were isotopically labelled and their plasma membrane distributions were
554 mapped by secondary ion mass spectrometry[159]. Detection of spatially dependent
555 variations in the analysis or lipid clustering was achieved by global labelling of most
556 lipids with carbon-13 and nitrogen-15 labelling of sphingolipids and its precursors (SM,
557 ceramide, glycosphingolipids)[159]. Scanning electron microscopy was first used to
558 identify well-reserved cells with intact micro-extensions and with normal morphologies
559 before analysis by secondary ion mass spectrometry[159]. Sphingolipids were found to
560 be enriched within membrane microdomains of about 200nm in diameter, larger than
561 what is expected for rafts in cells[159]. Although the sphingolipid domains organisation

562 and abundance were influenced by cholesterol, they were mainly altered by
563 cytoskeleton disruption, thus domains were proposed to not resemble lipid rafts but
564 rather distinct sphingolipid assemblies [159].

565 Mass spectrometry methodologies allow the identification of lipidomic membrane
566 changes during tumorigenesis. Changes in lipid composition cause structural and
567 functional alterations in cell signalling that originate at the plasma membrane that are
568 detectable with mass spectrometry. More lipidomic studies are required to fully
569 understand the cellular composition and the architecture of cancer cells, especially
570 given the differences seen in different cancer cell types and stages, and under different
571 treatment strategies (for example drug resistance and metastasis). The rapidly
572 developing interest for studying cancer membranes and their properties as potential
573 lipid-targeted therapies, is at least in part due to these mass spectrometry techniques
574 that have demonstrated measurable alterations of cancer membrane lipid composition
575 (Figure 2). Once these compositional changes are well established, methodologies with
576 higher spatial resolution (Figure 3) should be fully exploited to identify and link
577 membrane properties (driven by composition changes) to the oncogenic signalling
578 pathways that are affected.

579 **4. Computational Biophysics**

580 **4.1. Molecular Dynamic Simulations**

581 Computational methods such as molecular dynamics (MD) simulations have been used
582 to study the dynamics, interactions and functions of membranes and of membrane
583 proteins[160, 161] (Figure 4). MD techniques are considered as a computational
584 microscope, providing details for membrane organisation/dynamics at the molecular
585 level. Atomistic molecular dynamics (AT-MD) simulations, whilst more detailed, can be
586 computationally expensive and thus lower resolution simulation techniques e.g.
587 coarse-grained molecular dynamics (CG-MD) simulations[162] are also used. In CG-MD
588 simulations rather than simulating every atom, groups of atoms are simulated as a bead
589 and are given the physico-chemical properties of that group, in a process termed
590 parametrisation. In this way larger or more complex systems can be simulated for a

591 longer time course, at the expense of losing information on every atomic interaction.
592 CG-MD simulations were widely used to provide insights into cancer related protein-
593 lipid and lipid-lipid interactions and dynamics.

594 4.2. MD studies of complex membranes and with lateral heterogeneity

595 MD simulations can provide useful molecular insights into membranes as well as their
596 properties e.g. lipid-lipid interactions and fluidity (Figure 4). While most studies employ
597 vastly simplified model membranes because much of the complex behaviour of
598 membrane can be recreated with just three species in both experiment and simulation
599 (namely high and low T_m lipids and cholesterol) there may be unforeseen subtleties
600 that are lost. Simulation can recreate the complexity of the plasma membrane.
601 Studying the complexity and the asymmetric nature of the plasma membrane is
602 particularly important, especially since, in cancer membrane asymmetry is lost. MD
603 simulations can study the structural changes seen in tumorigenesis in an atomic level
604 and for a fixed period of time to understand in detail the membrane properties involved
605 in these changes. Furthermore, as previously discussed, an increase in cholesterol
606 content is observed in some cancer cells/tissues and subsequently there is an
607 enrichment of cholesterol-rich membrane domains and lateral heterogeneity. The
608 details of lipid-lipid interactions that drive lateral heterogeneity, which is seen in cancer
609 cells, can be studied with simulations over time in controlled conditions.

610 Recently, MD simulations of multicomponent systems that more closely resemble
611 membranes found in various cell types and organisms at different cell stages have been
612 performed[160]. Ingolfsson *et al.* simulated an asymmetric plasma membrane model
613 consisting of 63 different lipid species[163]. This study suggested enrichment of
614 cholesterol and ganglioside nanodomain formation in the outer leaflet, and
615 phosphoinositide clustering in the inner leaflet of the plasma membrane. L_o domain
616 formation and disappearance was observed at the microsecond time-scale[163].
617 Simulations of a model of the asymmetric human brain plasma membrane showed that
618 although the neuronal plasma membrane has a different lipid composition and is
619 enriched in cholesterol, its bilayer properties were similar with the previously-
620 simulated average plasma membrane[164]. Andoh *et al.* used MD to simulate two

621 complex PM models of the normal and the cancer thymocyte membrane and observed
622 changes in membrane properties following cancer development[165]. Koldsø *et al.*
623 used MD simulations to study an asymmetric plasma membrane consisting of 1500
624 lipids and observed the formation of lipid nano-clusters of glycolipids and to a lesser
625 extent of PI(4,5)P₂ lipids[166]. Furthermore, the same study showed that cytokine
626 receptor gp130 co-clusters with glycolipids (GM3)[166]. Other simulation studies also
627 showed formation of glycolipids/protein nano-domains[167].

628 Lateral heterogeneity and the coexistence of L_o and L_d phases in membranes, their
629 properties and the effects of such heterogeneity in oncogenic protein function has
630 been widely studied by MD simulations. AT-MD simulations also showed that the
631 membrane permeability of the chemotherapy drug cisplatin is decreased upon increase
632 in cholesterol concentration or when the membrane asymmetry is lost[88]. Sodt *et al.*
633 used AT-MD to elucidate the molecular structure of the L_o phase[168]. CG-MD
634 simulation studies showed that an increase in steroid headgroup hydrophobicity move
635 them from the canonical upright orientation, towards the centre of the bilayer in a
636 vertical orientation, thus disrupting domain formation[169]. Moiset *et al.* also used a
637 CG-MD simulation approach to study how disaccharides can destabilise phase
638 separation accompanied by other experimental techniques. In this study, liquid-
639 ordered domains were disrupted by non-reducing disaccharides (sucrose, trehalose),
640 but not by monosaccharides (glucose) resulting in uniformly mixed membranes[170].
641 CG-MD simulations were also used to explore equimolar binary mixtures of a saturated
642 lipid with di-unsaturated lipids of differing chain lengths to provide information about
643 their mixing behaviour and local composition-induced changes in their molecular
644 structure. Rosetti *et al.* showed that saturated lipids tails become less ordered in di-
645 unsaturated-rich lipid regions. Also, longer unsaturated lipid tail length induces a better
646 mixing with saturated lipids[171]. A later study also focused on unsaturated lipids
647 suggesting that the greater the unsaturation the better the stability of lipid
648 domains[172].

649 Cholesterol not only affects the ordering, fluidity, and thickness of the plasma
650 membrane, but may also have an amplifying role in signal transduction across the two

651 membrane leaflets. MD simulations revealed that cholesterol flip-flop impacts
652 nanodomains registration demonstrating that it may play a role in the transfer of
653 information between the leaflets[173]. Cholesterol undergoes oxidative modification,
654 through reactive oxygen species (ROS) to form tail-oxidised sterols, named
655 oxysterols[174]. Kulig *et al.* used AT-MD simulations to suggest a mechanism by which
656 sterols rapidly translocate in cellular compartments, referred to as bobbing[175].
657 Bobbing was observed only with a sterol that contained an additional hydroxyl group at
658 the sterol tail. They suggested that this occurs at the nanosecond timescale and is
659 potentially responsible for facilitating rapid translocation of different sterols from
660 cellular compartments to their receptors, without changing their orientation.

661 MD simulations of lipid-only systems provided detailed information on the structure
662 and function of the plasma membrane. Understanding the structural properties of
663 membrane lipids is particularly important for studies that involve oncogenic proteins
664 that sit in the lipid environment. Knowing the effects of lipid-only systems of complex
665 and asymmetric membranes and their properties could help estimate and understand
666 the relationship between protein-lipid interactions later on.

667 4.3. MD simulations of signalling receptors

668 Molecular dynamics simulations have also been used to provide insights into the
669 function and interactions of signalling receptors e.g. to study lipid interactions with
670 receptor tyrosine kinases (RTK)[176] as well as the oligomerization of transmembrane
671 helices[177]. RTKs reside in mammalian cell membranes and play a significant role in
672 initiating signalling cascades and de-regulated oncogenic cell growth. Hedger *et al.*
673 studied all 58 known human RTKs using a multiscale computational simulation
674 approach and observed that the juxtamembrane (JM) regions of RTKs interact with
675 anionic lipids[176]. More specifically PIP₂ lipids had the highest contacts with JM
676 residues, particularly the N-terminal end of the JM regions, followed by PS and PC
677 lipids[176].

678 CG- and AT-MD simulations have helped reveal the mechanism of dimerization and
679 activation of the ephrin (Eph) receptor family, the largest of RTKs, and critical to cell

680 migration. Chavent *et al.* studied the changes in the transmembrane region of EphA
681 that happen during EphA activation[178]. Their simulations revealed 2 distinct states
682 of the EphA transmembrane helix dimer as well as possible paths from one state to
683 another[179]. Understanding the mechanistic dynamic behaviour of RTKs is important
684 for cancer drug design that target these receptors[178]. MD simulation studies also
685 showed the importance of phosphatidylinositol phosphates (PIPs) in facilitating kinase
686 domain-membrane interaction at the cytoplasmic surface of the cell membrane[179].
687 For example, CG simulations showed that the kinase and juxtamembrane domain
688 region of the EphA2 receptor, interact with PIP lipids, resulting in nanoclustering of
689 these lipids in the vicinity of the receptor. This PIP nanoclustering around the receptor
690 potentially results in recruiting more receptors and facilitating autophosphorylation of
691 the kinase domains of adjacent receptor dimers[179]. Additionally, a number of MD
692 simulation studies focused on the association of the TM region of ErbB and the effect
693 of lipids on this association[180-184].

694 Halim *et al.* showed that PIP₂ lipids interact strongly with the EGFR juxtamembrane (JM)
695 domain[185]. This may explain why epidermal growth factor (EGF)-induced EGFR
696 activity decreases in membranes containing fewer PIP₂ membrane lipids[185, 186].
697 Another study showed that 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (POPS)
698 lipids interact with basic residues in the (JM) segments of the EGFR stabilising the JM
699 helix dimer[187]. This stabilisation strengthened the coupling between the
700 extracellular and the intracellular modules of the EGFR[187]. Using AT-MD simulations
701 Kaszuba *et al.* showed that *N*-glycosylation of the EGFR ectodomain significantly affects
702 its orientation and its interactions with the membrane[188]. This observation was also
703 supported by Arkhipov *et al.* which suggested that the flexibility of glycans permitted
704 the EGFR ectodomains to rest on the membrane[189]. MD simulations of the fibroblast
705 growth factor receptor 3 (FGFR3) suggested a shift of the mutant dimer (G380R in its
706 transmembrane domain) towards the outer membrane leaflet to allow arginine
707 sidechain/ phosphate lipid head group interactions[190].

708 The family of heterodimeric receptors, integrins, are potential cancer therapeutic
709 targets through their involvement in various signalling pathways, including tumour

710 metastasis[191, 192]. MD methodologies revealed that cholesterol and PS lipids cluster
711 around the integrin/talin complex, potentially facilitating the receptor activity and
712 signal transduction events[193]. More specifically Kalli *et al.* performed CG-MD
713 simulations of an asymmetrical model membrane that consisted of five different lipid
714 types and showed that integrin changed the lipid in its vicinity[193]. This simulation
715 showed elevated density of cholesterol and PS lipids close to the integrin receptor due
716 to interactions of lipids with the integrin/talin F2-F3 complex[193]. PIP₂ lipids were also
717 suggested to play an important role in stabilising an integrin/talin heterocomplex[194].
718 Other studies used MD simulations to study the mechanism for integrin activation[195,
719 196] and the role of integrin-lipid interaction[196]. Guo *et al.* suggested that the ionic
720 interplay of a Lys residue in the integrin α L β 2 with acidic phospholipids and calcium
721 ions in T cells regulates integrin function[196].

722 4.4. MD simulations of peripheral membrane proteins involved in signalling

723 The interaction of peripheral membrane proteins (PMPs) with lipids at the membrane
724 surface is critical for cellular functions, including cell signalling[197, 198]. This
725 interaction is facilitated by lipid-binding modules located on many PMPs, which bind to
726 specific membrane lipids, such as PIPs[199]. The pleckstrin homology (PH) domain is
727 one such example. Yamamoto *et al.* studied the formation of the PH/PIP complexes of
728 13 different PH domains, including the Akt-PH domain that is important for cancer cell
729 signalling. PH domains were found to associate with PIP lipids via a highly positively
730 charged loop and that clustering of PIP molecules occurs upon binding of the PH
731 domain to the lipid bilayer[199]. Comparison with experimental PH/PIP structures
732 showed that the predicted PH/PIP complexes are in good agreement with NMR and X-
733 ray crystallography data of PH/PIP headgroup complexes[199]. Buyan *et al.* explored
734 the formation of the Dok PH/membrane complex, a protein that is required along with
735 membrane lipids to activate MuSK receptor tyrosine kinase (MuSK)[200]. Using CG- and
736 AT-MD simulations, this study suggested that DOK7-PH domain associates with PIP
737 containing membranes, via a positively charged surface on the PH domain that
738 interacts with the headgroups of PIP lipids. Clustering of PIP molecules was also
739 observed[200]. MD simulations also provided insights into the localisation and diffusion

740 of PH domains on PIP-containing lipid bilayers suggesting that the diffusivity of the PH
741 domains is regulated by the number of PIP lipids that are bound to the PH domain[198,
742 201]. Furthermore, using MD simulations and mechanochemical network simulations
743 forces from the PIP₂-containing membranes and from the cytoskeleton were found to
744 activate focal adhesion kinase (FAK)[202].

745 K-Ras is another example of a peripheral membrane protein that is attached to the
746 inner leaflet of the plasma membrane. K-Ras regulates numerous signalling pathways
747 and its somatic mutations are linked to about 15-20% of all human cancers. Prakash *et al.*
748 used MD simulations in conjunction with biological assays, to study K-Ras and their
749 association with a negatively-charged bilayer, rich in PS lipids[203]. Their study revealed
750 that a constitutively active oncogenic mutant on K-Ras directly interacts with the
751 membrane in multiple orientations[203]. In two orientations that are more prominent
752 the catalytic domain interacts with the bilayer[203]. Janosi *et al.* suggested that 4-10
753 H-Ras molecules assemble and segregate into clusters in domain-forming mixed
754 bilayers or non-domain-forming bilayers. This group noticed that clusters of H-Ras were
755 larger and more stable in the domain-forming than the non-domain-forming bilayers,
756 and that localisation occurred at the L_o/L_d domain interphase[204]. Cholesterol was
757 found to enhance H-Ras nanocluster domain stability[205] but it was not required for
758 their formation. Other CG-MD simulations also indicated that in phase-separating
759 membranes, H-Ras nano-or/and large clusters mainly concentrate at the domain
760 boundary[205]. A CG-MD simulation by Jefferys *et al.* observed similar localisation for
761 N-Ras and suggested that the protein slows the rate of the formation of membrane
762 domains[206]. Additionally, Li *et al.* suggested using models representing the active or
763 the inactive state of Ras molecules, indicate a single large aggregate, but protein-
764 protein interactions are different depending on activity state [207].

765 Arcario *et al.* used MD simulations with a highly mobile membrane mimetic model
766 (HMMM) to study the protein talin, which is essential for integrin receptor activation
767 at the plasma membrane. They observed a conformational change within the talin F2-
768 F3 domain upon binding to the membrane [208]. Simulations with the complete talin
769 head domain showed that it adopts a V-shaped configuration upon binding to the

770 membrane that may stabilise its interactions with the membrane[209]. MD simulations
771 revealed important information about molecular mechanisms and specific
772 protein/membrane lipid interactions, of other peripheral membrane proteins like the
773 phosphatase and the tumour suppressor tensin homologue (PTEN) [210].

774 4.5. Quantification of membrane proteins interaction with lipids

775 Measuring interactions between lipids and proteins provides valuable information
776 regarding which lipid species are strong candidate drug targets. MD simulations of free
777 energy can be used to quantify the strength of lipid/protein interaction[211].

778 Hedger *et al.* compared the free energy of the interactions between the TM helix dimer
779 of wild type and mutant EGFR receptor with GM3 and PIP₂ lipids with potential of mean
780 force (PMF) calculations. Mutations at modulatory sites of the EGFR decreased the free
781 energy of GM3 and of PIP₂ lipids[212]. Chan *et al.* used PMF calculations to show that
782 PIP₂ molecules bind stronger to two binding sites of ACAP1-PH domain compared to
783 POPS[213]. Naughton *et al.* used CG-MD simulations in conjunction with PMF
784 calculations to quantify the free energy of binding of the GRP1 PH domain to PIP₂ and
785 PIP₃ lipid molecules and showed preferential binding of GRP1 PH to PIP₃ compared to
786 PIP₂ lipids. In the presence of mutations in the PIP binding site, the primary orientation
787 of the PH domain to the bilayer was not observed[211], indicating that PIP lipids may
788 be important for GRP1 protein binding and signalling pathway initiation. In a recent
789 study the same methodologies were used to study the strength of protein/lipid
790 interactions of 12 PH domains with PIP₂ and PIP₃ lipids[214]. Lu *et al.* used Molecular
791 Mechanics-Poisson-Boltzmann Surface Area (MM/PBSA) calculations to measure
792 binding free energy of protein/ligand systems and explore the interaction behaviour of
793 wild-type and 11 mutants of the PH domain in Bruton's tyrosine kinase (Btk) protein
794 with inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5)P₄)[215]. These free energy
795 calculations distinguished the mutations in two groups, the "folding" and "functional"
796 mutations, the former resulting in the loss of function of the PH domain and the latter
797 disrupting the binding affinities between the Btk/Ins(1,3,4,5)P₄ interactions, but
798 without affecting the overall fold[215]. The same approach was used by Rosen *et al.* to
799 understand the affinity of PKB PH domain to inositol phosphate head-groups that play

800 a role in the PI3K pathway[216]. This MD study agreed with the 3-phosphorylated
801 phosphoinositide selectivity observed *in vivo*[216]. They also proposed that Ins (1,3,5)
802 P₃ lipids, that are produced from PI(4,5)P₂, lipids and were shown to not bind Akt *in*
803 *vivo*, can bind Akt if their inositol ring is flipped with respect to their parent lipid and
804 the 3-phosphorylated inositol phosphate ligands and if not bonded to a phosphatidate
805 tail[216].

806 Simulations provided insightful information about transmembrane proteins, which are
807 extremely difficult to crystallise from aqueous solution. Not only MD simulations
808 provide structural predictions about proteins, they also provide information about how
809 these proteins interact with their lipid environment over time. MD simulations are
810 reliable prediction tools for studying various aspects of the membrane in detail not
811 accessible by typical wet-lab, or semi-dry experimental set-ups.

812 5. Membrane Biophysics

813 5.1. Membrane dynamics and interactions

814 Techniques for measuring lipid diffusion, membrane dynamics and interactions include
815 fluorescence correlation spectroscopy (FSC) (single molecule or several molecules),
816 Förster Resonance Energy Transfer (FRET) (can be ensemble or single-molecule-based)
817 and single particle tracking (SPT), a single-molecule method. Single-molecule based
818 techniques have been used for assessing molecular heterogeneities in biological
819 membranes through the incorporation of single particles, such as labelled proteins and
820 tracking their behaviour[217]. They are often fluorescence based and are extensively
821 used for the study of membrane proteins and their interactions in live cells. Single-
822 molecule methods allow observations of individual interactions in high mechanistic
823 detail, rather than the effect of millions of interactions in an ensemble average. Single-
824 molecule approaches are useful in studying how individual molecules behave over time
825 and how they change in conformation and properties. Unlike population techniques,
826 single-molecule approaches provide details regarding intermolecular variations (static
827 disorder) of individual molecules (such as protein folding)[218] and allow tracking of
828 the random and stochastic dynamics for various processes[219]. Furthermore, the

829 molecular structure of macromolecules as well as their structural and functional
830 response to mechanical manipulation of molecules and how they change their
831 conformation or properties can be studied with single-molecule methodologies[218].

832 5.1.1. Fluorescence Correlation Spectroscopy

833 FCS coupled to confocal microscopy measures fluorescence intensity fluctuations in the
834 small confocal volume as a function of time to generate diffusion coefficients and
835 particle concentrations with high temporal resolution[220](Figure 3). The overall
836 fluorescence intensity and the particle number fluctuate around an average value thus
837 providing information on the particle dynamics, states of aggregation and molecular
838 interactions[221] (Figure 4). FCS techniques have been applied to study membrane
839 receptor dynamics of Rous sarcoma virus membrane interactions in living cells by
840 analysing the interactions between labelled Lyn kinase and FCER1 receptor after
841 stimulation with fluorescently labelled IgE[222]. FCS was also used to study the
842 contribution of lateral membrane organisations in the PI3K/Akt signalling pathway
843 activation. This study suggested that membrane nanodomains potentially contribute
844 to the majority of PI3K mediated signalling events and that PIP₃-containing
845 nanodomains are only formed when PIP₃ binds to PH domain[223]. Gerken *et al.* used
846 FCS to study the membrane dynamics of two plasma membrane receptors, tumor
847 necrosis factor receptor 1 and 2, TNFR1 and TNFR2, respectively[224]. This study
848 observed enhanced diffusion of TNFR1 upon cholesterol depletion and no changes at
849 diffusion constant of TNFR2 upon cholesterol depletion suggesting potential
850 microcompartment-plasma membrane topological segregation of the two
851 receptors[224]. While FCS has been widely used for studying protein and lipid dynamics
852 in model membranes or *in vivo*, it has a relatively lower spatial resolution (diffraction
853 limited) compared to other techniques, like Single Particle Tracking (SPT)[225] (Figure
854 3).

855 5.1.2. Single Particle Tracking

856 SPT is a single-molecule technique that traces the path of multiple particles down to a
857 precision of nanometres, tracking their detailed positions and velocities. The high

858 temporal and spatial resolution of SPT (Figure 3) make it a powerful technique for
859 studying dynamic membrane events such as particle aggregation/dissociation and
860 lateral diffusion (Figure 4). SPT has been applied to study Lck tyrosine kinase localisation
861 to membrane microdomains in T cells and their role in cell signalling; phosphorylation
862 and dephosphorylation balance[226], as well as EGFR related cell signalling[227].
863 Furthermore SPT has been used for identifying changes in diffusion of proteins (EGFR,
864 HER2, I-Ek) upon modulating membrane cholesterol concentration[228] and Ras
865 activation following EGF and insulin activation[229]. Lommerse *et al.* studied the
866 relationship between the activation of H-Ras, which is part of Ras family of proteins
867 that regulate cancer cell growth and membrane microdomain localisation in live cells
868 using single-molecule fluorescence microscopy[229]. In this study a constitutively
869 inactive mutant H-Ras and a constitutively inactive mutant were fused to enhanced
870 yellow fluorescent protein (eYFP)[229]. Both forms showed a major fast-diffusing
871 population and a minor low-diffusing population of H-Ras. The slow-diffusing
872 population of the active mutant was restricted to 200nm membrane domains, which
873 were calculated by mobility analysis of populations of molecules [229]. While this was
874 not observed for the inactive mutant, upon insulin-activation the slow-diffusing
875 population of H-Ras in the wild-type was also confined to the membrane domains[229].
876 This study showed that there is a relationship between membrane microdomains and
877 H-Ras activation [229].

878 5.1.3. Förster Resonance Energy Transfer

879 FRET based techniques have been applied to model membranes and live cells for
880 studying interactions of species such as docking, protein-protein interactions, protein-
881 lipid interactions and signalling on a membrane surface[230] (Figure 4) by using
882 fluorophores that are coupled to the proteins of interest. FRET is a powerful technique
883 that can reveal nanodomains that are not visible by light microscopy[231] (Figure 3)
884 and utilises transfer of excited-emission from the donor to the sensitised emission of
885 the acceptor; the efficiency of transfer informs on the distance between the donor and
886 acceptor[232]. The Förster expression predicts that the efficiency of this transfer is
887 inversely proportional to the 6th power of this distance ($1/R^6$), which typically indicates

888 that resolution on the scale of 1-10nm are possible[233]. FRET approach allows
889 studying the spatial relationships of molecules including nanoscale protein interactions
890 and changes in protein conformational states (Figure 4).

891 While variations in the sample intensity can make it difficult to determine the transfer
892 efficiency based on the donor emission, this artefact, can be eliminated with the use of
893 Fluorescence Lifetime Imaging (FLIM) in conjunction with FRET (discussed later). FRET
894 was used to study the activity of a genetically encodable fluorescent kinase reporter,
895 AktAR in different microdomains of the plasma membrane of live cells[234]. Activation
896 of Akt and its downward signalling cascades were enriched in lipid raft domains in
897 comparison to non-lipid raft domains of the plasma membrane[234]. This genetically
898 encoded Akt activity reporter could be detected by FRET in a large dynamic range, and
899 was sensitive in detecting changes in Akt activity upon treatment of Akt inhibitors[234].
900 The green fluorescent protein (GFP) has been used in association to FRET to visualise
901 the flow of signalling cascades in live cells through monitoring protein-protein
902 interactions and conformational changes in living cells[235]. More specifically FRET was
903 applied for the visualisation of Rac[236], and Ras protein activation, which are involved
904 in cancer cell proliferation using bimolecular fluorescent indicators[237]. In a similar
905 approach, Murakoshi *et al.* observed activated Ras molecules that immobilised in the
906 cell membrane and the potential formation of a signalling complex of activated Ras in
907 a subline of the ubiquitous keratin-forming tumour cells[238], in agreement to single-
908 molecule techniques; SPT[229]. In combination with phospho-specific antibodies, GFP
909 fusion proteins were used as donors in FRET to study autophosphorylation of protein
910 kinase C alpha (PKC α)[239] and EGFR activation [222, 240] in the plasma membrane of
911 fixed cells. Issiki *et al.* used FRET to show that caveolae are involved in signal
912 transduction pathways in living cells by using genetically engineered Ca²⁺ probes,
913 named cameleon proteins. This engineered calcium sensor yellow cameleon was
914 shown to target the plasma membrane caveolae in preference to the endoplasmic
915 reticulum, indicating Ca²⁺ controlled signalling machinery to be functionally organised
916 in the L_o of the plasma membrane; caveolae[241]. Tyrosine kinases and their
917 phosphorylation status are good markers of cell signalling activation and their
918 phosphorylation is often a marker of increased cell signalling and cell growth in cancer.

919 Unimolecular indicators constructed from an appropriate phosphorylation substrate
920 peptide and a phospho-amino acid binding domain were genetically linked to form a
921 hybrid protein and were then observed by fluorescent mutants[231, 242]. In
922 combination to confocal microscopy, FRET was utilised to determine the efficiency of
923 osteopontin (OPN-R3) in inhibiting the tumorigenesis inducing OPN binding to its cell
924 surface receptors (CD44, avb3 integrin) in breast cancer cells[243].

925 Homo-FRET is a less utilized form of FRET, where two identical fluorophores are used
926 that overlap between excitation and emission spectra but differ in fluorescence
927 polarisation. Only a single fluorescent probe is required, with the ability to monitor
928 intracellular events in real time with a microplate reader in the nanometre scale.
929 Homo-FRET in association with fluorescence anisotropy measurements has been used
930 to assess the oligomerization state of biological macromolecules in their native
931 environment, which plays a fundamental role in signal transduction. In particular,
932 studies on glycosyl-phosphatidylinositol-anchored proteins (GPI-APs) clustering used
933 homo-FRET to observe the modulation of GPI-anchoring upon depletion of cholesterol
934 and sphingolipids that resulted in loss of homo-FRET in live cells. Using the same
935 approach, they suggested the presence of small clusters of proteins that act as
936 platforms for GPI-APs and suggested their potential of being crucial for signal
937 transduction[244, 245]. GPIs are evenly distributed in the surface of resting cells and
938 are enriched in DRMs suggesting that clustering of cell surface receptors may induce L_o
939 microdomain formation. These methodologies were able to show that small alterations
940 in protein or lipid aggregation are able to highly influence membrane domain
941 organisation, and facilitation of protein-protein interactions.

942

943 FCS, SPT and FRET methods provided useful information on the mobility of molecules
944 in their membrane environments. In combination with fluorescence dyes SPT and FRET
945 are capable of operating in complex biological systems such as live cancer cells in a
946 single molecule sensitivity rather than an ensemble average. Alterations in diffusion
947 constants in membranes indirectly depict lateral heterogeneities, which interact with

948 oncogenic proteins, findings which can be directly seen using from microscopes and
949 super resolution.

950 5.2. Microscopies

951 Biophysical changes in molecular packing and membrane phase separation indicates
952 changes in cell functioning. Thus, physical methods for studying the whole cell
953 membrane, including diffusion, bending (curvature), fluidity, rigidity and how they
954 change in various conditions and external stresses have been extensively applied
955 (Figure 4).

956 5.2.1. Fluorescence Lifetime Imaging Microscopy

957 FLIM microscopy maps the spatial distribution of fluorescence lifetimes at the
958 nanosecond level. FLIM has been previously used for measuring membrane properties
959 using environment-sensitive probes, like solvatochromic dyes, which change their
960 colour in response to change in polarity, viscosity and order[117, 246]. Combined
961 FRET/FLIM allows for detecting spatiotemporal protein-protein interactions and has
962 been employed as an improved method for the assessment of FRET in association with
963 multiphoton microscopy[247]. Multiphoton microscopy gives a better axial sectioning
964 compared to other optical imaging approaches (wide-field, confocal microscopy),
965 improves z resolution and allows penetration into deep samples like tissue, with less
966 toxicity[247]. Multiphoton microscopy with combined FRET/FLIM has been widely
967 applied for studying invasion and metastasis with sub-cellular resolution in vivo[247]
968 (Figure 4).

969 Chemokine Receptor Type 4 (CXCR4) promotes metastasis in breast, prostate,
970 pancreatic and hematopoietic origin tumours and is consistently upregulated in human
971 breast cancer cells[248]. Peter *et al.* used FRET detection by multiphoton FLIM to
972 characterise ligand binding of the CXCR4 chemokine receptor and protein kinase C
973 (PKC) of MDA-MB-231 breast cancer carcinoma cells using EGFP (donor) and mRFP11
974 (acceptor) as their fluorophores, respectively [249]. Ahmed and colleagues also
975 employed FRET/FLIM (on a multiphoton microscope) in prostate cancer cells and

976 observed that p21 activated kinase (PAK4- Rho family GTPases) binds to and
977 phosphorylates LIM kinase 1 (LIMK1), downstream of hepatocyte growth factor (HGF)
978 to increase cell migration speed[250]. As with the previous group Mrfp1 and GFP were
979 used as donor and acceptor, respectively.

980 5.2.2. Atomic Force Microscopy

981 Atomic Force Microscopy (AFM) provides sub-nanometre resolution and can be used
982 to image biological systems with minimum sample preparation and with no
983 requirement for fluorescent dye incorporation (although the use of dyes is commonly
984 utilised)[251]. A sharp probe approaches the sample that sits on an atomically flat
985 surface and provides information on the distance-dependent interaction forces,
986 generating 3D topography maps of biological samples in air or in their native liquid
987 environment. As a result, information for the biological's specimen morphology and
988 structure is generated. AFM has been used extensively for the study of lateral
989 heterogeneities in membranes, since it can provide information on the height of
990 nanodomains[251, 252] (Figure 4).

991 Giocondi *et al.* were the first to use AFM to study the effect of membrane phase
992 separation on protein partitioning and the association with cell signalling[253]. In
993 agreement to later findings[153], they observed clustering and filament formation in
994 the SM and cholesterol rich domains, upon the cholera toxin receptor addition to the
995 model membrane system showing complete insolubility to the L_o phase. AFM
996 techniques also showed the accumulation of cholera toxin protein in L_o domains[239].
997 Yuan *et al.* also linked the behaviour of lipid phases in model membranes and function
998 in real cells by visualising the effect of ganglioside G_{M1} distribution on the overall phase
999 structure[254, 255]. In agreement with the other studies, it was observed that G_{M1}
1000 localised in the L_o phase and thus G_{M1} were considered to be a marker for L_o domains.
1001 These domains were too small to be observed with fluorescence microscopy since they
1002 are in the nanometre scale, thus making the AFM approach very useful.

1003 Membrane phase separation has been observed when a combination of AFM and FCS
1004 was applied for studying membrane phase separation[236, 256] and membrane

1005 proteins within L_o and L_d phase compartments. Orsini *et al.* extracted membrane
1006 patches of human triple negative breast cancer cells (MDA-MB-231) by Triton X-100
1007 and sucrose gradient ultracentrifugation and used AFM and antibody-based techniques
1008 to study membrane domains in breast cancer cells. AFM provided evidence of
1009 microdomains with lateral dimensions of 100-500nm, extending from the membrane
1010 patches by 1-2nm with a greater roughness compared to the smoother surrounding
1011 membrane[257]. Treatment of samples antibodies against flotillin-1 (lipid-raft marker)
1012 showed increase in micro-domain surface area suggesting the presence of flotillin-1 in
1013 the AFM visualised microdomains[257]. These results were further supported by
1014 immunoblotting and high-performance thin liquid chromatography that also detected
1015 high cholesterol, SM and flotillin-1 content in the membrane microdomains of breast
1016 cancer cells [257]. The authors discussed the use of detergents for the membrane
1017 patches extraction and stated that their observations are in agreement with Pathak *et*
1018 *al.* (a FRET study) that showed detergents to increase domain size by coalescing pre-
1019 existing domains rather than inducing their formation[258]. The authors also suggested
1020 that AFM applications could greatly contribute in the study of membrane
1021 microdomains in healthy and cancer membranes providing high spatial resolution, in
1022 physiological-like conditions, without the need for fixation, staining or labelling of
1023 cells[257]. Lamprecht *et al.* used AFM to study the mechanisms of the plasma
1024 membrane interaction of Hsp70-1A with PS lipids in the presence and absence of
1025 cholesterol, which was previously linked to resistance to cancer radiotherapy,
1026 metastasis and poor prognosis[259]. This study highlighted a strong association
1027 between the plasma membrane Hsp70-1A and the negatively charged saturated PS
1028 lipids[259, 260], which are enriched in cancer cells[259]. PS lipids were sufficient for
1029 Hsp70-1A insertion to the membrane[259]. In the presence of cholesterol, the L_o phase
1030 emerged, which was about 1.2nm greater in height than the surrounding lipid
1031 phase[259]. Upon cholesterol addition, Hsp70-1A protein was found to be clustering in
1032 the L_o phase[259]. Increase of protein concentration in the presence of cholesterol
1033 resulted in in the onset of membrane blebbing[259]. According to the authors[259] the
1034 formation of membrane blebs that burst at higher concentrations are potentially linked

1035 to the previously proposed non-classical pathway for the export of Hsp70-1A by tumour
1036 cells[261].

1037 In combination with biological assays, Pommier *et al.* used AFM to study the role of
1038 Liver X Receptors (LXRs) in regulating cholesterol homeostasis in prostate cancer cells
1039 and observed smaller and thinner L_o domains post LXR stimulation[124]. Furthermore,
1040 this study suggested cholesterol to be an important modulator domain formation, since
1041 cell membrane replenishment with cholesterol reversed the LXR-induced results on the
1042 L_o domains[124]. Rivera *et al.* used a new fast scanning quantitative dynamic AFM
1043 method to observe rapid changes in the cytoskeletal architecture at the cell periphery
1044 of breast cancer cells and the activity of Syk protein tyrosine kinase[262]. This
1045 technique allowed studying of the time varying heterogeneous physical properties of
1046 live cells, by using the cantilever mean deflection as feedback signal rather than
1047 standard amplitude reduction, resulting in increased temporal resolution to capture
1048 dynamic changes in cellular properties[262]. As already mentioned, leaking of PS[54]
1049 and PE[52] lipids from the inner to the outer membrane leaflet in cancer results in loss
1050 of membrane asymmetry in cancer cells. In combination with fluorescence confocal
1051 microscopy Leite *et al.* used AFM to study the membrane interaction with the
1052 antimicrobial peptide Polybia-MP1, which shows anti-cancerous effects[60]. They
1053 observed PS lipids to significantly facilitate binding of MP1 peptide to the membrane
1054 through charge interactions and the role of PE lipids in potentiating the formation of
1055 larger transmembrane pores due to the particular shape of PE molecule stabilising the
1056 pores[60]. Alvares *et al.* also suggested synergy between PS lipids and L_o domains and
1057 proposed that PS is required for the Polybia-MP1 to apply its membrane lytic action,
1058 while membrane order can influence this activity and facilitate its binding to the
1059 membrane[263].

1060 Quintela *et al.* used AFM in live cells along with biological assays to define the molecular
1061 function of histone acetyltransferase (HBO1), which is highly expressed in ovarian
1062 cancer[264]. This group showed that HBO1 increases the cell membrane elasticity in
1063 ovarian cancer cells[264]. A recent study explored the interactions of the GDP-bound
1064 form of K-RAS4b, a proto-oncogene with anionic lipids using AFM and MD

1065 simulations[265]. K-RAS4b-GDP appeared to be more loosely associated with the PS-
1066 containing membrane, compared to the PIP₂-containing membrane[265]. Another AFM
1067 study explored the regulatory mechanisms of destruxin resistance phenotypes, which
1068 has anticancer activity[266]. This study observed hyper-activity of the mevalonate
1069 pathway and de-novo cholesterol synthesis, associated with increased cell membrane
1070 adhesiveness of the resistant lines compared to the parental cell lines[266]. Sakai *et al.*
1071 used AFM and showed that the targeted breast cancer drug Trastuzumab has a
1072 significant effect on the biological membrane by modulating the membrane fluidity and
1073 the formation of phases within the membrane of different fluidity levels[267]. A more
1074 in depth analysis of how AFM has been applied to cancer research and cancer cell
1075 morphology, elasticity and adhesion properties is available in a recent expert review
1076 (see review [268]).

1077 Powerful microscopy techniques provide a new opportunity for fluorescence-based
1078 techniques resolving structures in high spatial resolution, while maintaining the
1079 capabilities of optical fluorescence microscopy for complex biological structures. AFM
1080 and FLIM, combined together or with other techniques (AFM/FLIM and FRET/FLIM)
1081 provided significant progress in studying important properties of the plasma
1082 membrane including lateral heterogeneity, molecular aggregation, diffusion, fluidity,
1083 thickness in cancer cells and identified alterations in cancer cell morphology that relate
1084 to the membrane composition.

1085 5.3. Label Free Techniques

1086 Label Free techniques overcome various limitations of fluorescence-based techniques,
1087 explaining why their use is exponentially increasing. As already mentioned, if not
1088 chosen wisely fluorescent probes can affect the native environment of the labelled
1089 molecule, alter its conformation and the function of the labelled protein, or oligomerize
1090 and fluoresce non-specifically[269].

1091 5.3.1. Surface plasmon resonance microscopy

1092 Surface plasmon resonance microscopy (SPRM) label free technique, which can
1093 measure protein-binding kinetics with the use of a sensor chip coated with membranes
1094 to prevent the disruption of the native environment of membrane proteins[270]. SRPM
1095 ensures intact native conformations of the plasma membrane and can also be coupled
1096 with fluorescence techniques allowing for optical and fluorescence imaging of the same
1097 sample, thus having the advantages of both label-free and label based methodologies
1098 in one experiment[270]. Wang *et al.* used SPRM simultaneously with optical
1099 transmission and immunofluorescence microscopy of the same sample to study how
1100 membrane glycoproteins and nicotinic acetylcholine (nAChRs) interact with their
1101 ligands; lectin in single cells and their polarization during chemotaxis[270]. Chemotaxis
1102 is involved in invasion, intravasation, extravasation of carcinoma cells, which are crucial
1103 steps in cell dissemination and metastasis [271].

1104 5.3.2. Small-angle x-ray scattering

1105 The effect of bilayer properties and cholesterol on cell signalling initiation and its
1106 potential role in biological disease such as cancer explains the use of indirect
1107 techniques on studying membrane biology. Small-angle x-ray scattering (SAXS) is a
1108 powerful technique, appropriate for examining the structure as well as the elastic
1109 parameters of fluid membranes under near-physiological conditions. Over the years, it
1110 provided critical insights to the current lipid membrane structure knowledge. It is based
1111 on X-ray diffraction, where a beam of X-rays exposes the membrane and scatters its
1112 electrons in all directions[272]. Several SAXS studies contributed important information
1113 into phase separation and the formation of L_o domains, suggesting their potential
1114 contribution in providing an additional environment for the assembly of membrane
1115 proteins[273-277]. SAXS provided insights to the extent of structural changes in
1116 receptor tyrosine kinase EGFR dimerization upon the presence or the absence of its
1117 ligand and suggested that its activation is not necessarily ligand dependent[278].
1118 Hodzic *et al.* applied SAXS to investigate the responses of cholesterol incorporation in
1119 model bilayers in comparison to phytosterols, which are compounds that are known to
1120 decrease cholesterol concentration in the plasma membrane and good candidates to

1121 be used as therapeutic agents in cancer. In comparison to cholesterol, stigmasterol and
1122 sitosterol differ by an additional double bond and ethyl group, respectively, showed a
1123 reduced condensing effect indicating that small variations in the bilayer sterol structure
1124 could modulate the lipid bilayer composition in a biologically meaningful manner[279].
1125 This indirectly opens a way to research cancer therapeutics involving substances that
1126 are capable to modulate cholesterol concentration and other membrane parameters.

1127 5.3.3. Electron microscopy and cryo-EM

1128 Electron microscopy has provided important insights for nanoscopic lipid domains[118,
1129 280]. Prior *et al*, used electron microscopy to directly visualise Ras proteins in spatially
1130 distinct cell surface domains and suggested that wild-type H-Ras is distributed in a
1131 dynamic equilibrium between cholesterol rich-ordered domains and other non-
1132 cholesterol-dependent microdomains[281]. As already mentioned, similar findings
1133 were found by MD simulations[204]. They also found an inner-plasma membrane raft
1134 marker (GFP-tH) to display cholesterol-dependent clustering in membrane
1135 microdomains[281]. The latest advancements in cryogenic electron microscopy
1136 (cryoEM) in intact cells may provide a reliable methodology for studying the biological
1137 significance of lateral organisation in biological membranes. Cryo-EM like SAXS, allows
1138 for sub-angstrom level resolution, but provides direct imaging instead. Heberle *et al*.
1139 recently used cryoEM to image nanodomains in model membranes and isolated intact
1140 plasma membrane vesicles (GPMV) from rat-basophilic leukaemia cells and showed
1141 similar nanoscale lateral heterogeneities between the two[103]. Although the use of
1142 cryo-EM in studying membrane biology holds promising, more studies are required to
1143 validate these findings using this technique.

1144 Label free techniques complement some high-resolution fluorescent-based
1145 microscopy methods by maintaining a high spatial resolution without having risks of
1146 affecting the native environment of the sample. Comparison of label-free and label-
1147 based techniques can indicate appropriate probes that are non-invasive to the native
1148 structure of the membrane or the membrane protein being studied.

1149 6. Conclusion

1150 Biological membrane properties and membrane organisation at the nanometre scale
1151 are fundamental in cellular bioactivity via lipid-lipid and lipid-protein interactions and
1152 have critical roles in tumorigenesis. For this reason, a range of anti-cancer lipid-
1153 targeting drugs have been in clinical or pre-clinical drug developmental stages. Some
1154 examples include Perifosine that targets the cell membrane and membrane domain
1155 organisation[282] (Phase I-III clinical trials for solid and non-solid tumours), Nelfinavir
1156 that disrupts lipid homeostasis (Phase II for glioblastoma, pancreatic, lung cancers)[43,
1157 283] and the PS-targeting antibody Bavituximab for cancer detection and cancer
1158 immunotherapy[284] (Phase I-III for advanced solid tumours non-small cell lung cancer,
1159 breast, pancreatic and hepatocellular cancers). While effective in pre-clinical work,
1160 their effectiveness in clinical trials requires a better lipid-centered perspective and
1161 understanding on their mechanism and action in cancer cells. Unlike protein and
1162 nucleic-acid targeting drugs, drugs targeting lipogenesis are newer and still entail less
1163 understanding in their mode of action to prove their effectiveness. Overall,
1164 cholesterol-rich membrane domains can both worsen (multi-drug resistance) and
1165 improve (aggressive metastasis) cancer outcomes, highlighting an unmet clinical need
1166 for more studies identifying the role of the plasma membrane and lateral heterogeneity
1167 in various stages, severity and types of cancer. Techniques widely used in the past, such
1168 as detergent resistance membranes, although being a useful empirical tool, do not
1169 precisely identify membrane domains, and are prone to induce experimental artefacts.
1170 The advancement in methodologies with high temporal and spatial resolution allows
1171 researchers to acquire direct evidence and expand the findings of previous
1172 methodologies. The combination of direct label-free techniques, like cryo-EM, non-
1173 direct label-free techniques (SPRM, SAXS) and the collaborative use of fluorescent
1174 labelling in whole cells or GPMVs, with quantitative diffusion measurement techniques
1175 (FCS, SPT, FRET), microscopy (AFM, FLIM) and computational biology will be critical in
1176 understanding the roles of membrane properties in cancer and lipid-targeted
1177 therapies. The potential application of some of these techniques, like AFM in the clinical
1178 setting and diagnosis for determining ultrastructure and mechanical properties of the
1179 tumours and cells such as the morphology, elasticity, rigidity and fluidity has been

1180 reviewed recently[268, 285, 286]. The severity of tumours in clinic is mostly
1181 qualitatively examined by immunostaining and optical microscopy, [287] where tissue
1182 is fixed and loses its mechanical property characteristics. The capability of AFM in
1183 complementing histopathological data based on rheological properties in advanced
1184 colon cancer tissues was recently evaluated[288]. The application of AFM for future
1185 clinical diagnosis of metastatic and chemoresistant live cells guided by the properties
1186 of the cell membrane could open new opportunities, provide both quantitative and
1187 qualitative information in early detection and improve cancer prognosis. In addition,
1188 simulations provide mechanistic detail at the molecular level but require strong
1189 experimental evidence to validate its findings. A good temporal resolution allows
1190 tracking of biological dynamic processes, accurately time localising rapid changes and
1191 a good spatial resolution allows for direct detection of the dynamic membrane
1192 properties. This is especially important since domains in model membranes seem to be
1193 more easily detected being in the microscopic scale, whereas in live cells remain
1194 nanoscopic[122]. All techniques have their strengths and weaknesses, operating over
1195 different time and length scales, and the combination of two or more usually essential
1196 to verify the findings and bridge the biophysical observations to the biological function.
1197 It is required that cancer biologists studying the membrane collaborate and utilise high-
1198 resolution biophysical techniques along with biological assays to answer critical
1199 biological questions on membrane role in cancer as it is required by the nature of these
1200 dynamic processes. To conclude, membranes and their lipids must be studied using
1201 collaborative research to accurately and rapidly advance understanding of the cell
1202 membrane and its components in lipid-targeted cancer therapeutics.

1203 **Funding Sources**

1204 CS was funded by University of Leeds Global Challenge Interdisciplinary Doctoral
1205 Scholarship.

1206 Credit Author Statement

1207 Chrysa Soteriou: Conceptualization, Methodology, Formal Analysis, Investigation,
1208 Writing – Original Draft, Writing – Review and Editing, Visualisation. Antreas Kalli:
1209 Writing – Review and Editing, Supervision, Funding Acquisition, Resources. Simon
1210 Connell: Writing – Review and Editing, Supervision, Funding Acquisition. Arwen Tyler:
1211 Writing – Review and Editing, Supervision, Funding Acquisition. James L Thorne:
1212 Conceptualization, Writing – Review and Editing, Supervision, Funding Acquisition,
1213 Resources.

1214 Figure Legends

1215 **Figure 1 The structure and physical properties of the membrane.** Properties such as
1216 membrane thickness, lateral diffusion (translational freedom), bond rotation
1217 (configuration freedom or lipid ordering), lipid flip-flop are shown in red lines/arrows.
1218 L_o ; liquid-ordered domains, L_d ; liquid-disordered domains.

1219 **Figure 2 The plasma membrane.** A) The asymmetric distribution of lipids in the plasma
1220 membrane. B) Coarse-Grained and all-atom representation of a phosphatidylcholine
1221 lipid and the major lipids comprising the plasma membrane. C) Membrane asymmetry
1222 in healthy and cancer cells. D) Overall changes in lipid components of the membrane
1223 in different cancer types. Full details are found in supplementary tables. SM;
1224 Sphingomyelin, PC; Phosphatidylcholine, PE; Phosphatidylethanolamine, PS;
1225 Phosphatidylserine, PI; Phosphatidylinositol, CHOL; Cholesterol, MDR; Multi-Drug
1226 Resistance.

1227 **Figure 3 The spatiotemporal resolution of methodologies used to study the cancer**
1228 **plasma membrane and the relevant biological processes involved in signaling through**
1229 **the plasma membrane.** AT-MD; Atomistic Molecular Dynamic Simulations, CG-MD;
1230 Coarse-Grained Molecular Dynamic Simulations, FCS; Fluorescence Correlation
1231 Spectroscopy; SPT; Single-Particle Tracking, SPRM; Surface Plasmon Resonance
1232 Microscopy, FRET; Förster resonance energy transfer, AFM; Atomic Force Microscopy,
1233 SAXS; Small Angle X-ray Scattering, EM; Electron Microscopy, cryo-EM; Cryogenic-
1234 Electron Microscopy

1235 **Figure 4 Properties of the plasma membrane that are involved in cancer and the**
1236 **methodologies that can be used for each.** MD; Molecular Dynamics Simulations, IF;
1237 Immunofluorescence, WB; Western Blotting, IP; Immunoprecipitation, MS; Mass
1238 Spectrometry, FCS; Fluorescence Correlation Spectroscopy; SPT; Single-Particle
1239 Tracking, AFM; Atomic Force Microscopy, FRET; Förster resonance energy transfer,
1240 FLIM; Fluorescence Lifetime Imaging Microscopy, SPRM; Surface Plasmon Resonance
1241 Microscopy, SAXS; Small Angle X-ray Scattering, EM; Electron Microscopy, cryo-EM;
1242 Cryogenic-Electron Microscopy

1243 **References**

- 1244 [1] F.M. Goni, The basic structure and dynamics of cell membranes: an update of the
1245 Singer-Nicolson model, *Biochim Biophys Acta* 1838(6) (2014) 1467-76.
- 1246 [2] A. Palko-Labuz, K. Sroda-Pomianek, O. Wesolowska, E. Kostrzewa-Suslow, A. Uryga, K.
1247 Michalak, MDR reversal and pro-apoptotic effects of statins and statins combined with
1248 flavonoids in colon cancer cells, *Biomedicine & pharmacotherapy = Biomedecine &*
1249 *pharmacotherapie* 109 (2019) 1511-1522.
- 1250 [3] T. Skotland, S. Kavaliauskiene, K. Sandvig, The role of lipid species in membranes and
1251 cancer-related changes, *Cancer Metastasis Rev* 39(2) (2020) 343-360.
- 1252 [4] G.L. May, L.C. Wright, M. Dyne, W.B. Mackinnon, R.M. Fox, C.E. Mountford, Plasma
1253 membrane lipid composition of vinblastine sensitive and resistant human leukaemic
1254 lymphoblasts, *Int J Cancer* 42(5) (1988) 728-33.
- 1255 [5] R. Bandu, H.J. Mok, K.P. Kim, Phospholipids as cancer biomarkers: Mass spectrometry-
1256 based analysis, *Mass Spectrom Rev* 37(2) (2018) 107-138.
- 1257 [6] N. Azordegan, V. Fraser, K. Le, L.M. Hillyer, D.W. Ma, G. Fischer, M.H. Moghadasian,
1258 Carcinogenesis alters fatty acid profile in breast tissue, *Mol Cell Biochem* 374(1-2) (2013)
1259 223-32.
- 1260 [7] J.F. Hancock, Lipid rafts: contentious only from simplistic standpoints, *Nat Rev Mol*
1261 *Cell Biol* 7(6) (2006) 456-62.
- 1262 [8] K. Simons, E. Ikonen, Functional rafts in cell membranes, *Nature* (1997).
- 1263 [9] J.L. Liyan Zhuang, Michael L. Lu, Keith R. Solomon and Michael R. Freeman,
1264 Cholesterol-rich Lipid Rafts Mediate Akt-regulated Survival in Prostate Cancer Cells,
1265 *Cancer Research* (2002).
- 1266 [10] R.J. Romanelli, K.R. Mahajan, C.G. Fulmer, T.L. Wood, Insulin-like growth factor-I-
1267 stimulated Akt phosphorylation and oligodendrocyte progenitor cell survival require
1268 cholesterol-enriched membranes, *J Neurosci Res* 87(15) (2009) 3369-77.
- 1269 [11] J. Kopecka, P. Trouillas, A.C. Gasparovic, E. Gazzano, Y.G. Assaraf, C. Riganti,
1270 Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic
1271 targets, *Drug Resist Updat* 49 (2020) 100670.
- 1272 [12] F. Fenyvesi, E. Fenyvesi, L. Szente, K. Goda, Z. Bacso, I. Bacskay, J. Varadi, T. Kiss, E.
1273 Molnar, T. Janaky, G. Szabo, Jr., M. Vecsernyes, P-glycoprotein inhibition by membrane

- 1274 cholesterol modulation, *European journal of pharmaceutical sciences : official journal of*
1275 *the European Federation for Pharmaceutical Sciences* 34(4-5) (2008) 236-42.
- 1276 [13] J.N. Cash, N.R. Chandan, A.Y. Hsu, P.V. Sharma, Q. Deng, A.V. Smrcka, J.J.G. Tesmer,
1277 *Discovery of Small Molecules That Target the Phosphatidylinositol (3,4,5) Trisphosphate*
1278 *(PIP3)-Dependent Rac Exchanger 1 (P-Rex1) PIP3-Binding Site and Inhibit P-Rex1-*
1279 *Dependent Functions in Neutrophils, Molecular pharmacology* 97(3) (2020) 226-236.
- 1280 [14] B. Oskouian, J.D. Saba, *Cancer treatment strategies targeting sphingolipid*
1281 *metabolism, Adv Exp Med Biol* 688 (2010) 185-205.
- 1282 [15] M.L. Sulciner, A. Gartung, M.M. Gilligan, C.N. Serhan, D. Panigrahy, *Targeting lipid*
1283 *mediators in cancer biology, Cancer Metastasis Rev* 37(2-3) (2018) 557-572.
- 1284 [16] A.T. Srivatsav, M. Mishra, S. Kapoor, *Small-Molecule Modulation of Lipid-Dependent*
1285 *Cellular Processes against Cancer: Fats on the Gunpoint, Biomed Res Int* 2018 (2018)
1286 6437371.
- 1287 [17] L.T. Tan, K.G. Chan, P. Pusparajah, W.L. Lee, L.H. Chuah, T.M. Khan, L.H. Lee, B.H. Goh,
1288 *Targeting Membrane Lipid a Potential Cancer Cure?, Front Pharmacol* 8 (2017) 12.
- 1289 [18] B. Sharma, S.S. Kanwar, *Phosphatidylserine: A cancer cell targeting biomarker, Semin*
1290 *Cancer Biol* 52(Pt 1) (2018) 17-25.
- 1291 [19] F. Elvas, S. Stroobants, L. Wyffels, *Phosphatidylethanolamine targeting for cell death*
1292 *imaging in early treatment response evaluation and disease diagnosis, Apoptosis* 22(8)
1293 (2017) 971-987.
- 1294 [20] G. van Meer, D.R. Voelker, G.W. Feigenson, *Membrane lipids: where they are and how*
1295 *they behave, Nat Rev Mol Cell Biol* 9(2) (2008) 112-24.
- 1296 [21] O. Quehenberger, A.M. Armando, A.H. Brown, S.B. Milne, D.S. Myers, A.H. Merrill, S.
1297 Bandyopadhyay, K.N. Jones, S. Kelly, R.L. Shaner, C.M. Sullards, E. Wang, R.C. Murphy, R.M.
1298 Barkley, T.J. Leiker, C.R. Raetz, Z. Guan, G.M. Laird, D.A. Six, D.W. Russell, J.G. McDonald, S.
1299 Subramaniam, E. Fahy, E.A. Dennis, *Lipidomics reveals a remarkable diversity of lipids in*
1300 *human plasma, Journal of lipid research* 51(11) (2010) 3299-305.
- 1301 [22] P.V. Escriba, J.M. Gonzalez-Ros, F.M. Goni, P.K. Kinnunen, L. Vigh, L. Sanchez-
1302 Magraner, A.M. Fernandez, X. Busquets, I. Horvath, G. Barcelo-Coblijn, *Membranes: a*
1303 *meeting point for lipids, proteins and therapies, Journal of cellular and molecular*
1304 *medicine* 12(3) (2008) 829-75.
- 1305 [23] S.J. Singer, G.L. Nicolson, *The fluid mosaic model of the structure of cell membranes,*
1306 *Science* 175(4023) (1972) 720-31.
- 1307 [24] R.J. Clarke, K.R. Hossain, K. Cao, *Physiological roles of transverse lipid asymmetry of*
1308 *animal membranes, Biochim Biophys Acta Biomembr* 1862(10) (2020) 183382.
- 1309 [25] M.S. Almen, K.J. Nordstrom, R. Fredriksson, H.B. Schioth, *Mapping the human*
1310 *membrane proteome: a majority of the human membrane proteins can be classified*
1311 *according to function and evolutionary origin, BMC Biol* 7 (2009) 50.
- 1312 [26] R.W. Robey, K.M. Pluchino, M.D. Hall, A.T. Fojo, S.E. Bates, M.M. Gottesman, *Revisiting*
1313 *the role of ABC transporters in multidrug-resistant cancer, Nature reviews. Cancer* 18(7)
1314 (2018) 452-464.
- 1315 [27] B. Alberts, *Molecular biology of the cell, 4th ed., Garland Science, New York, 2002.*
- 1316 [28] J.P. Overington, B. Al-Lazikani, A.L. Hopkins, *How many drug targets are there?, Nat*
1317 *Rev Drug Discov* 5(12) (2006) 993-6.

- 1318 [29] A. Rutkowska, E. Stoczynska-Fidelus, K. Janik, A. Wlodarczyk, P. Rieske, EGFR(vIII):
1319 An Oncogene with Ambiguous Role, *J Oncol* 2019 (2019) 1092587.
- 1320 [30] C. Ceci, M.G. Atzori, P.M. Lacal, G. Graziani, Role of VEGFs/VEGFR-1 Signaling and its
1321 Inhibition in Modulating Tumor Invasion: Experimental Evidence in Different Metastatic
1322 Cancer Models, *Int J Mol Sci* 21(4) (2020).
- 1323 [31] P.H. Wu, A.E. Opadele, Y. Onodera, J.M. Nam, Targeting Integrins in Cancer
1324 Nanomedicine: Applications in Cancer Diagnosis and Therapy, *Cancers (Basel)* 11(11)
1325 (2019).
- 1326 [32] C.R. Santos, A. Schulze, Lipid metabolism in cancer, *Febs J* 279(15) (2012) 2610-23.
- 1327 [33] U. Ray, S.S. Roy, Aberrant lipid metabolism in cancer cells - the role of oncolipid-
1328 activated signaling, *Febs J* 285(3) (2018) 432-443.
- 1329 [34] M. Sok, M. Sentjurc, M. Schara, J. Stare, T. Rott, Cell membrane fluidity and prognosis
1330 of lung cancer, *Ann Thorac Surg* 73(5) (2002) 1567-71.
- 1331 [35] W. Szlasa, I. Zendran, A. Zalesinska, M. Tarek, J. Kulbacka, Lipid composition of the
1332 cancer cell membrane, *J Bioenerg Biomembr* (2020).
- 1333 [36] R. Zeisig, T. Koklic, B. Wiesner, I. Fichtner, M. Sentjurc, Increase in fluidity in the
1334 membrane of MT3 breast cancer cells correlates with enhanced cell adhesion in vitro and
1335 increased lung metastasis in NOD/SCID mice, *Arch Biochem Biophys* 459(1) (2007) 98-
1336 106.
- 1337 [37] S. Donatello, I.S. Babina, L.D. Hazelwood, A.D. Hill, I.R. Nabi, A.M. Hopkins, Lipid raft
1338 association restricts CD44-ezrin interaction and promotion of breast cancer cell
1339 migration, *The American journal of pathology* 181(6) (2012) 2172-87.
- 1340 [38] H. Raghu, P.K. Sodadasu, R.R. Malla, C.S. Gondi, N. Estes, J.S. Rao, Localization of uPAR
1341 and MMP-9 in lipid rafts is critical for migration, invasion and angiogenesis in human
1342 breast cancer cells, *BMC Cancer* 10 (2010) 647.
- 1343 [39] A. Badana, M. Chintala, G. Varikuti, N. Pudi, S. Kumari, V.R. Kappala, R.R. Malla, Lipid
1344 Raft Integrity Is Required for Survival of Triple Negative Breast Cancer Cells, *J Breast
1345 Cancer* 19(4) (2016) 372-384.
- 1346 [40] S. Tiwary, J.A. Berzofsky, M. Terabe, Altered Lipid Tumor Environment and Its
1347 Potential Effects on NKT Cell Function in Tumor Immunity, *Front Immunol* 10 (2019)
1348 2187.
- 1349 [41] L. Gil-de-Gomez, D. Balgoma, O. Montero, Lipidomic-Based Advances in Diagnosis
1350 and Modulation of Immune Response to Cancer, *Metabolites* 10(8) (2020).
- 1351 [42] D. Lankry, T.L. Rovis, S. Jonjic, O. Mandelboim, The interaction between CD300a and
1352 phosphatidylserine inhibits tumor cell killing by NK cells, *Eur J Immunol* 43(8) (2013)
1353 2151-61.
- 1354 [43] S. Beloribi-Djefafli, S. Vasseur, F. Guillaumond, Lipid metabolic reprogramming in
1355 cancer cells, *Oncogenesis* 5 (2016) e189.
- 1356 [44] A.B. Hendrich, K. Michalak, Lipids as a target for drugs modulating multidrug
1357 resistance of cancer cells, *Curr Drug Targets* 4(1) (2003) 23-30.
- 1358 [45] M. Hilvo, C. Denkert, L. Lehtinen, B. Muller, S. Brockmoller, T. Seppanen-Laakso, J.
1359 Budczies, E. Bucher, L. Yetukuri, S. Castillo, E. Berg, H. Nygren, M. Sysi-Aho, J.L. Griffin, O.
1360 Fiehn, S. Loibl, C. Richter-Ehrenstein, C. Radke, T. Hyotylainen, O. Kallioniemi, K. Iljin, M.
1361 Oresic, Novel theranostic opportunities offered by characterization of altered membrane
1362 lipid metabolism in breast cancer progression, *Cancer Res* 71(9) (2011) 3236-45.

- 1363 [46] E. Cifkova, M. Holcapek, M. Lisa, D. Vrana, J. Gatek, B. Melichar, Determination of
1364 lipidomic differences between human breast cancer and surrounding normal tissues
1365 using HILIC-HPLC/ESI-MS and multivariate data analysis, *Anal Bioanal Chem* 407(3)
1366 (2015) 991-1002.
- 1367 [47] T.E. Merchant, D. Characiejus, J.N. Kasimos, W. Den Otter, L.W. Gierke, T. Glonek,
1368 Phosphodiesterases in saponified extracts of human breast and colon tumors using ³¹P
1369 magnetic resonance spectroscopy, *Magn Reson Med* 26(1) (1992) 132-40.
- 1370 [48] C.L. Silva, R. Perestrelo, I. Sousa-Ferreira, F. Capelinha, J.S. Camara, M. Petkovic, Lipid
1371 biosignature of breast cancer tissues by matrix-assisted laser desorption/ionization time-
1372 of-flight mass spectrometry, *Breast Cancer Res Treat* 182(1) (2020) 9-19.
- 1373 [49] G.M. Eberlin LS, Fan AC, Gouw AM, Tibshirani RJ, Felsher DW, Zare RN, Eberlin LS,
1374 Gabay M, Fan AC, Gouw AM, Tibshirani RJ, Felsher DW et al. Alteration of the lipid profile
1375 in lymphomas induced by MYC overexpression., *Proc Natl Acad Sci U S A* (2014).
- 1376 [50] A. Zachowski, Phospholipids in Animal Eukaryotic Membranes - Transverse
1377 Asymmetry and Movement, *Biochemical Journal* 294 (1993) 1-14.
- 1378 [51] P.F. Devaux, Protein involvement in transmembrane lipid asymmetry, *Annual review*
1379 *of biophysics and biomolecular structure* 21 (1992) 417-39.
- 1380 [52] J.H. Stafford, P.E. Thorpe, Increased exposure of phosphatidylethanolamine on the
1381 surface of tumor vascular endothelium, *Neoplasia* 13(4) (2011) 299-308.
- 1382 [53] S. Ran, A. Downes, P.E. Thorpe, Increased exposure of anionic phospholipids on the
1383 surface of tumor blood vessels, *Cancer Res* 62(21) (2002) 6132-40.
- 1384 [54] H. Woehlecke, A. Pohl, N. Alder-Baerens, H. Lage, A. Herrmann, Enhanced exposure
1385 of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC
1386 transporter BCRP (ABCG2), *Biochem J* 376(Pt 2) (2003) 489-95.
- 1387 [55] S. Riedl, B. Rinner, S. Tumer, H. Schaidler, K. Lohner, D. Zweytick, Targeting the cancer
1388 cell membrane specifically with human lactoferricin derivatives, *Ann Oncol* 22 (2011) 33-
1389 33.
- 1390 [56] T. Utsugi, A.J. Schroit, J. Connor, C.D. Bucana, I.J. Fidler, Elevated Expression of
1391 Phosphatidylserine in the Outer-Membrane Leaflet of Human Tumor-Cells and
1392 Recognition by Activated Human Blood Monocytes, *Cancer Research* 51(11) (1991) 3062-
1393 3066.
- 1394 [57] R.L. Edwards, F.R. Rickles, T.E. Moritz, W.G. Henderson, L.R. Zacharski, W.B. Forman,
1395 C.J. Cornell, R.J. Forcier, J.F. O'Donnell, E. Headley, et al., Abnormalities of blood
1396 coagulation tests in patients with cancer, *Am J Clin Pathol* 88(5) (1987) 596-602.
- 1397 [58] A. Pohl, H. Lage, P. Muller, T. Pomorski, A. Herrmann, Transport of
1398 phosphatidylserine via MDR1 (multidrug resistance 1)P-glycoprotein in a human gastric
1399 carcinoma cell line, *Biochem J* 365(Pt 1) (2002) 259-68.
- 1400 [59] L.G. Lima, R.Q. Monteiro, Activation of blood coagulation in cancer: implications for
1401 tumour progression, *Biosci Rep* 33(5) (2013).
- 1402 [60] N.B. Leite, A. Aufderhorst-Roberts, M.S. Palma, S.D. Connell, J. Ruggiero Neto, P.A.
1403 Beales, PE and PS Lipids Synergistically Enhance Membrane Poration by a Peptide with
1404 Anticancer Properties, *Biophys J* 109(5) (2015) 936-47.
- 1405 [61] H.J. Kaiser, D. Lingwood, I. Levental, J.L. Sampaio, L. Kalvodova, L. Rajendran, K.
1406 Simons, Order of lipid phases in model and plasma membranes, *Proc Natl Acad Sci U S A*
1407 106(39) (2009) 16645-50.

- 1408 [62] J.L. Sampaio, M.J. Gerl, C. Klose, C.S. Ejsing, H. Beug, K. Simons, A. Shevchenko,
1409 Membrane lipidome of an epithelial cell line, *Proc Natl Acad Sci U S A* 108(5) (2011) 1903-
1410 7.
- 1411 [63] C. Crespi, S. Quevedo, P. Roca, A. Palou, Glucose erythrocyte transporter in women
1412 with breast cancer: changes in lipid composition of erythrocyte membrane, *IUBMB Life*
1413 48(5) (1999) 531-7.
- 1414 [64] W.J. Van Blitterswijk, G. DE Veer, J.H. Krol, P. Emmelton, Comparative Lipid Analysis
1415 of Purified Plasma Membranes and Shed Extracellular Membrane Vesicles from Normal
1416 Murine Thymocytes and Leukemic GRSL Cells
1417 , *Biochimica et Biophysica Acta* (1982).
- 1418 [65] C. Peetla, R. Bhave, S. Vijayaraghavalu, A. Stine, E. Kooijman, V. Labhasetwar, Drug
1419 resistance in breast cancer cells: biophysical characterization of and doxorubicin
1420 interactions with membrane lipids, *Mol Pharm* 7(6) (2010) 2334-48.
- 1421 [66] A. Mazzoni, F. Trave, Cytoplasmic membrane cholesterol and doxorubicin
1422 cytotoxicity in drug-sensitive and multidrug-resistant human ovarian cancer cells, *Oncol*
1423 *Res* 5(2) (1993) 75-82.
- 1424 [67] A. Greife, J. Tukova, C. Steinhoff, S.D. Scott, W.A. Schulz, J. Hatina, Establishment and
1425 characterization of a bladder cancer cell line with enhanced doxorubicin resistance by
1426 mevalonate pathway activation, *Tumour Biol* 36(5) (2015) 3293-300.
- 1427 [68] B. Wang, X. Rong, E.N.D. Palladino, J. Wang, A.M. Fogelman, M.G. Martin, W.A. Alrefai,
1428 D.A. Ford, P. Tontonoz, Phospholipid Remodeling and Cholesterol Availability Regulate
1429 Intestinal Stemness and Tumorigenesis, *Cell Stem Cell* 22(2) (2018) 206-220 e4.
- 1430 [69] S.L. Liu, R. Sheng, J.H. Jung, L. Wang, E. Stec, M.J. O'Connor, S. Song, R.K. Bikkavilli, R.A.
1431 Winn, D. Lee, K. Baek, K. Ueda, I. Levitan, K.P. Kim, W. Cho, Orthogonal lipid sensors
1432 identify transbilayer asymmetry of plasma membrane cholesterol, *Nat Chem Biol* 13(3)
1433 (2017) 268-274.
- 1434 [70] J. Bi, T.A. Ichu, C. Zanca, H. Yang, W. Zhang, Y. Gu, S. Chowdhry, A. Reed, S. Ikegami,
1435 K.M. Turner, W. Zhang, G.R. Villa, S. Wu, O. Quehenberger, W.H. Yong, H.I. Kornblum, J.N.
1436 Rich, T.F. Cloughesy, W.K. Cavenee, F.B. Furnari, B.F. Cravatt, P.S. Mischel, Oncogene
1437 Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on
1438 Membrane Lipid Remodeling, *Cell Metab* 30(3) (2019) 525-538 e8.
- 1439 [71] M.A. Alfhili, D.A. Weidner, M.H. Lee, Disruption of erythrocyte membrane asymmetry
1440 by triclosan is preceded by calcium dysregulation and p38 MAPK and RIP1 stimulation,
1441 *Chemosphere* 229 (2019) 103-111.
- 1442 [72] J.W. St Clair, S. Kakuda, E. London, Induction of Ordered Lipid Raft Domain Formation
1443 by Loss of Lipid Asymmetry, *Biophys J* (2020).
- 1444 [73] Z. Zhao, D. Hao, L. Wang, J. Li, Y. Meng, P. Li, Y. Wang, C. Zhang, H. Zhou, K. Gardner,
1445 L.J. Di, CtBP promotes metastasis of breast cancer through repressing cholesterol and
1446 activating TGF-beta signaling, *Oncogene* 38(12) (2019) 2076-2091.
- 1447 [74] I.S. Babina, E.A. McSherry, S. Donatello, A.D. Hill, A.M. Hopkins, A novel mechanism of
1448 regulating breast cancer cell migration via palmitoylation-dependent alterations in the
1449 lipid raft affiliation of CD44, *Breast Cancer Res* 16(1) (2014) R19.
- 1450 [75] E. Fahy, S. Subramaniam, H.A. Brown, C.K. Glass, A.H. Merrill, Jr., R.C. Murphy, C.R.
1451 Raetz, D.W. Russell, Y. Seyama, W. Shaw, T. Shimizu, F. Spener, G. van Meer, M.S.
1452 VanNieuwenhze, S.H. White, J.L. Witztum, E.A. Dennis, A comprehensive classification
1453 system for lipids, *Journal of lipid research* 46(5) (2005) 839-61.

- 1454 [76] S. Dessi, B. Batetta, D. Pulisci, O. Spano, C. Anchisi, L. Tessitore, P. Costelli, F.M.
1455 Baccino, E. Aroasio, P. Pani, Cholesterol content in tumor tissues is inversely associated
1456 with high-density lipoprotein cholesterol in serum in patients with gastrointestinal
1457 cancer, *Cancer* 73(2) (1994) 253-8.
- 1458 [77] K. Kolanjiappan, C.R. Ramachandran, S. Manoharan, Biochemical changes in tumor
1459 tissues of oral cancer patients, *Clin Biochem* 36(1) (2003) 61-5.
- 1460 [78] Y.C. Li, M.J. Park, S.K. Ye, C.W. Kim, Y.N. Kim, Elevated levels of cholesterol-rich lipid
1461 rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-
1462 depleting agents, *The American journal of pathology* 168(4) (2006) 1107-18; quiz 1404-
1463 5.
- 1464 [79] U. Levin-Gromiko, V. Koshelev, P. Kushnir, S. Fedida-Metula, E. Voronov, D. Fishman,
1465 Amplified lipid rafts of malignant cells constitute a target for inhibition of aberrantly
1466 active NFAT and melanoma tumor growth by the aminobisphosphonate zoledronic acid,
1467 *Carcinogenesis* 35(11) (2014) 2555-66.
- 1468 [80] S.L. Veatch, S.L. Keller, Separation of liquid phases in giant vesicles of ternary
1469 mixtures of phospholipids and cholesterol, *Biophys J* 85(5) (2003) 3074-83.
- 1470 [81] G. Radeva, J. Perabo, F.J. Sharom, P-Glycoprotein is localized in intermediate-density
1471 membrane microdomains distinct from classical lipid rafts and caveolar domains, *Febs J*
1472 272(19) (2005) 4924-37.
- 1473 [82] J. Fosso-Tande, C. Black, S. G. Aller, L. Lu, R. D. Hills Jr, Simulation of lipid-protein
1474 interactions with the CgProt force field, *AIMS Molecular Science* 4(3) (2017) 352-369.
- 1475 [83] D. De Felice, A. Alaimo, Mechanosensitive Piezo Channels in Cancer: Focus on altered
1476 Calcium Signaling in Cancer Cells and in Tumor Progression, *Cancers (Basel)* 12(7)
1477 (2020).
- 1478 [84] P. Ridone, E. Pandzic, M. Vassalli, C.D. Cox, A. Macmillan, P.A. Gottlieb, B. Martinac,
1479 Disruption of membrane cholesterol organization impairs the activity of PIEZO1 channel
1480 clusters, *J Gen Physiol* 152(8) (2020).
- 1481 [85] J. Troost, H. Lindenmaier, W.E. Haefeli, J. Weiss, Modulation of cellular cholesterol
1482 alters P-glycoprotein activity in multidrug-resistant cells, *Molecular pharmacology* 66(5)
1483 (2004) 1332-9.
- 1484 [86] M.I. Oh, C.I. Oh, D.F. Weaver, Effect of Cholesterol on the Structure of Networked
1485 Water at the Surface of a Model Lipid Membrane, *J Phys Chem B* 124(18) (2020) 3686-
1486 3694.
- 1487 [87] A. Ramu, D. Glaubiger, I.T. Magrath, A. Joshi, Plasma membrane lipid structural order
1488 in doxorubicin-sensitive and -resistant P388 cells, *Cancer Res* 43(11) (1983) 5533-7.
- 1489 [88] T. Rivel, C. Ramseyer, S. Yesylevskyy, The asymmetry of plasma membranes and their
1490 cholesterol content influence the uptake of cisplatin, *Sci Rep-Uk* 9 (2019).
- 1491 [89] T. Rivel, C. Ramseyer, S. Yesylevskyy, Permeation of cisplatin through the membranes
1492 of normal and cancer cells: a molecular dynamics study, (2018).
- 1493 [90] A. Filippov, G. Oradd, G. Lindblom, The effect of cholesterol on the lateral diffusion of
1494 phospholipids in oriented bilayers, *Biophys J* 84(5) (2003) 3079-86.
- 1495 [91] M. Vrljic, S.Y. Nishimura, W.E. Moerner, H.M. McConnell, Cholesterol depletion
1496 suppresses the translational diffusion of class II major histocompatibility complex
1497 proteins in the plasma membrane, *Biophys J* 88(1) (2005) 334-47.

- 1498 [92] Y. Senju, M. Kalimeri, E.V. Koskela, P. Somerharju, H. Zhao, I. Vattulainen, P.
1499 Lappalainen, Mechanistic principles underlying regulation of the actin cytoskeleton by
1500 phosphoinositides, *Proc Natl Acad Sci U S A* 114(43) (2017) E8977-E8986.
- 1501 [93] H.A. Lucero, P.W. Robbins, Lipid rafts-protein association and the regulation of
1502 protein activity, *Arch Biochem Biophys* 426(2) (2004) 208-24.
- 1503 [94] F. Mollinedo, C. Gajate, Lipid rafts as major platforms for signaling regulation in
1504 cancer, *Adv Biol Regul* 57 (2015) 130-46.
- 1505 [95] S.N. Zaman, M.E. Resek, S.M. Robbins, Dual acylation and lipid raft association of Src-
1506 family protein tyrosine kinases are required for SDF-1/CXCL12-mediated chemotaxis in
1507 the Jurkat human T cell lymphoma cell line, *J Leukoc Biol* 84(4) (2008) 1082-91.
- 1508 [96] S.P. Thankamony, W. Knudson, Acylation of CD44 and its association with lipid rafts
1509 are required for receptor and hyaluronan endocytosis, *J Biol Chem* 281(45) (2006)
1510 34601-9.
- 1511 [97] L.J. Pike, X. Han, R.W. Gross, Epidermal growth factor receptors are localized to lipid
1512 rafts that contain a balance of inner and outer leaflet lipids: a shotgun lipidomics study, *J*
1513 *Biol Chem* 280(29) (2005) 26796-804.
- 1514 [98] M.G. Gutierrez, J. Deyell, K.L. White, L.C. Dalle Ore, V. Cherezov, R.C. Stevens, N.
1515 Malmstadt, The lipid phase preference of the adenosine A2A receptor depends on its
1516 ligand binding state, *Chem Commun (Camb)* 55(40) (2019) 5724-5727.
- 1517 [99] T. Nieto-Miguel, C. Gajate, F. Gonzalez-Camacho, F. Mollinedo, Proapoptotic role of
1518 Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated
1519 antileukemic therapy, *Oncogene* 27(12) (2008) 1779-87.
- 1520 [100] M.E. Irwin, N. Bohin, J.L. Boerner, Src family kinases mediate epidermal growth
1521 factor receptor signaling from lipid rafts in breast cancer cells, *Cancer Biol Ther* 12(8)
1522 (2011) 718-26.
- 1523 [101] S. Zalba, T.L. Ten Hagen, Cell membrane modulation as adjuvant in cancer therapy,
1524 *Cancer Treat Rev* 52 (2017) 48-57.
- 1525 [102] C.E. Cornell, A. Mileant, N. Thakkar, K.K. Lee, S.L. Keller, Direct imaging of liquid
1526 domains in membranes by cryo-electron tomography, *Proc Natl Acad Sci U S A* 117(33)
1527 (2020) 19713-19719.
- 1528 [103] F.A. Heberle, M. Doktorova, H.L. Scott, A.D. Skinkle, M.N. Waxham, I. Levental, Direct
1529 label-free imaging of nanodomains in biomimetic and biological membranes by cryogenic
1530 electron microscopy, *Proc Natl Acad Sci U S A* 117(33) (2020) 19943-19952.
- 1531 [104] G. van Meer, Cellular lipidomics, *EMBO J* 24(18) (2005) 3159-65.
- 1532 [105] E. Sezgin, H.J. Kaiser, T. Baumgart, P. Schwille, K. Simons, I. Levental, Elucidating
1533 membrane structure and protein behavior using giant plasma membrane vesicles, *Nat*
1534 *Protoc* 7(6) (2012) 1042-51.
- 1535 [106] D.M. Owen, M.A. Neil, P.M. French, A.I. Magee, Optical techniques for imaging
1536 membrane lipid microdomains in living cells, *Semin Cell Dev Biol* 18(5) (2007) 591-8.
- 1537 [107] B.D.K. R.A. Demel, The functions of sterols in membranes, *Biochim Biophys Acta-*
1538 *Reviews on Biomembranes* (1976).
- 1539 [108] J. Fantini, N. Garmy, R. Mahfoud, N. Yahy, Lipid rafts: structure, function and role in
1540 HIV, Alzheimer's and prion diseases, *Expert reviews in molecular medicine* 4(27) (2002)
1541 1-22.

1542 [109] D.A. Mannoek, R.N. Lewis, T.P. McMullen, R.N. McElhaney, The effect of variations in
1543 phospholipid and sterol structure on the nature of lipid-sterol interactions in lipid bilayer
1544 model membranes, *Chemistry and physics of lipids* 163(6) (2010) 403-48.

1545 [110] H.M.G. Barriga, R.V. Law, J.M. Seddon, O. Ces, N.J. Brooks, The effect of hydrostatic
1546 pressure on model membrane domain composition and lateral compressibility, *Phys
1547 Chem Chem Phys* 18(1) (2016) 149-155.

1548 [111] P. Uppamoochikkal, S. Tristram-Nagle, J.F. Nagle, Orientation of Tie-Lines in the
1549 Phase Diagram of DOPC/DPPC/Cholesterol Model Biomembranes, *Langmuir* 26(22)
1550 (2010) 17363-17368.

1551 [112] L.M. Obeid, C.M. Linardic, L.A. Karolak, Y.A. Hannun, Programmed cell death induced
1552 by ceramide, *Science* 259(5102) (1993) 1769-71.

1553 [113] R. Kolesnick, Ceramide: a novel second messenger, *Trends Cell Biol* 2(8) (1992)
1554 232-6.

1555 [114] D. Meder, M.J. Moreno, P. Verkade, W.L. Vaz, K. Simons, Phase coexistence and
1556 connectivity in the apical membrane of polarized epithelial cells, *Proc Natl Acad Sci U S A*
1557 103(2) (2006) 329-34.

1558 [115] S.A. Sanchez, M.A. Tricerri, E. Gratton, Laurdan generalized polarization fluctuations
1559 measures membrane packing micro-heterogeneity in vivo, *Proc Natl Acad Sci U S A*
1560 109(19) (2012) 7314-9.

1561 [116] D.M. Owen, D.J. Williamson, A. Magenau, K. Gaus, Sub-resolution lipid domains exist
1562 in the plasma membrane and regulate protein diffusion and distribution, *Nature
1563 communications* 3 (2012).

1564 [117] V. Kilin, O. Glushonkov, L. Herdly, A. Klymchenko, L. Richert, Y. Mely, Fluorescence
1565 lifetime imaging of membrane lipid order with a ratiometric fluorescent probe, *Biophys J*
1566 108(10) (2015) 2521-2531.

1567 [118] I. Levental, D. Lingwood, M. Grzybek, U. Coskun, K. Simons, Palmitoylation regulates
1568 raft affinity for the majority of integral raft proteins, *P Natl Acad Sci USA* 107(51) (2010)
1569 22050-22054.

1570 [119] Z. Gerstle, R. Desai, S.L. Veatch, Giant Plasma Membrane Vesicles: An Experimental
1571 Tool for Probing the Effects of Drugs and Other Conditions on Membrane Domain
1572 Stability, *Methods Enzymol* 603 (2018) 129-150.

1573 [120] T. Baumgart, A.T. Hammond, P. Sengupta, S.T. Hess, D.A. Holowka, B.A. Baird, W.W.
1574 Webb, Large-scale fluid/fluid phase separation of proteins and lipids in giant plasma
1575 membrane vesicles, *Proc Natl Acad Sci U S A* 104(9) (2007) 3165-70.

1576 [121] D. Lingwood, J. Ries, P. Schwille, K. Simons, Plasma membranes are poised for
1577 activation of raft phase coalescence at physiological temperature, *Proc Natl Acad Sci U S
1578 A* 105(29) (2008) 10005-10.

1579 [122] I. Levental, K.R. Levental, F.A. Heberle, Lipid Rafts: Controversies Resolved,
1580 Mysteries Remain, *Trends Cell Biol* 30(5) (2020) 341-353.

1581 [123] D.A.B.a.J.K. Rose, <Sorting of GPI-Anchored Proteins to glycolipid-enriched
1582 membrane subdomains during transport to the apical cell surface.pdf>, *Cell Press* (1992).

1583 [124] A.J. Pommier, G. Alves, E. Viennois, S. Bernard, Y. Communal, B. Sion, G. Marceau, C.
1584 Damon, K. Mouzat, F. Caira, S. Baron, J.M. Lobaccaro, Liver X Receptor activation
1585 downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate
1586 cancer cells, *Oncogene* 29(18) (2010) 2712-23.

1587 [125] R.M. Adam, N.K. Mukhopadhyay, J. Kim, D. Di Vizio, B. Cinar, K. Boucher, K.R.
1588 Solomon, M.R. Freeman, Cholesterol sensitivity of endogenous and myristoylated Akt,
1589 *Cancer Res* 67(13) (2007) 6238-46.

1590 [126] J.L. Macdonald, L.J. Pike, A simplified method for the preparation of detergent-free
1591 lipid rafts, *Journal of lipid research* 46(5) (2005) 1061-7.

1592 [127] P.F. Lenne, H. Rigneault, D. Marguet, J. Wenger, Fluorescence fluctuations analysis
1593 in nanoapertures: physical concepts and biological applications, *Histochem Cell Biol*
1594 130(5) (2008) 795-805.

1595 [128] E. Schnitzer, D. Lichtenberg, M.M. Kozlov, Temperature-dependence of the
1596 solubilization of dipalmitoylphosphatidylcholine (DPPC) by the non-ionic surfactant
1597 Triton X-100, kinetic and structural aspects, *Chemistry and physics of lipids* 126(1)
1598 (2003) 55-76.

1599 [129] D. Lichtenberg, F.M. Goni, H. Heerklotz, Detergent-resistant membranes should not
1600 be identified with membrane rafts, *Trends Biochem Sci* 30(8) (2005) 430-6.

1601 [130] S. Schuck, M. Honsho, K. Ekroos, A. Shevchenko, K. Simons, Resistance of cell
1602 membranes to different detergents, *Proc Natl Acad Sci U S A* 100(10) (2003) 5795-800.

1603 [131] H. Heerklotz, Triton promotes domain formation in lipid raft mixtures, *Biophys J*
1604 83(5) (2002) 2693-701.

1605 [132] S. Munro, Lipid rafts: elusive or illusive?, *Cell* 115(4) (2003) 377-88.

1606 [133] G. Weber, F.J. Farris, Synthesis and spectral properties of a hydrophobic fluorescent
1607 probe: 6-propionyl-2-(dimethylamino)naphthalene, *Biochemistry* 18(14) (1979) 3075-8.

1608 [134] T. Parasassi, E. Gratton, Membrane Lipid Domains and Dynamics as Detected by
1609 Laurdan Fluorescence, *Journal of Fluorescence* (1995).

1610 [135] F. Foglia, M.J. Lawrence, C.D. Lorenz, S.E. McLain, On the hydration of the
1611 phosphocholine headgroup in aqueous solution, *The Journal of chemical physics* 133(14)
1612 (2010) 145103.

1613 [136] C. Das, K.H. Sheikh, P.D. Olmsted, S.D. Connell, Nanoscale mechanical probing of
1614 supported lipid bilayers with atomic force microscopy, *Phys Rev E Stat Nonlin Soft Matter*
1615 *Phys* 82(4 Pt 1) (2010) 041920.

1616 [137] G. M'Baye, Y. Mely, G. Duportail, A.S. Klymchenko, Liquid ordered and gel phases of
1617 lipid bilayers: fluorescent probes reveal close fluidity but different hydration, *Biophys J*
1618 95(3) (2008) 1217-25.

1619 [138] E. Sezgin, I. Levental, M. Grzybek, G. Schwarzmann, V. Mueller, A. Honigmann, V.N.
1620 Belov, C. Eggeling, U. Coskun, K. Simons, P. Schwille, Partitioning, diffusion, and ligand
1621 binding of raft lipid analogs in model and cellular plasma membranes, *Biochim Biophys*
1622 *Acta* 1818(7) (2012) 1777-84.

1623 [139] A.P. Demchenko, Y. Mely, G. Duportail, A.S. Klymchenko, Monitoring biophysical
1624 properties of lipid membranes by environment-sensitive fluorescent probes, *Biophys J*
1625 96(9) (2009) 3461-70.

1626 [140] A.L. Obaid, L.M. Loew, J.P. Wuskell, B.M. Salzberg, Novel naphthylstyryl-pyridium
1627 potentiometric dyes offer advantages for neural network analysis, *J Neurosci Methods*
1628 134(2) (2004) 179-90.

1629 [141] L. Jin, A.C. Millard, J.P. Wuskell, X. Dong, D. Wu, H.A. Clark, L.M. Loew,
1630 Characterization and application of a new optical probe for membrane lipid domains,
1631 *Biophys J* 90(7) (2006) 2563-75.

- 1632 [142] D.M. Owen, C. Rentero, A. Magenau, A. Abu-Siniyeh, K. Gaus, Quantitative imaging of
1633 membrane lipid order in cells and organisms, *Nat Protoc* 7(1) (2011) 24-35.
- 1634 [143] D.M. Owen, P.M. Lanigan, C. Dunsby, I. Munro, D. Grant, M.A. Neil, P.M. French, A.I.
1635 Magee, Fluorescence lifetime imaging provides enhanced contrast when imaging the
1636 phase-sensitive dye di-4-ANEPPDHQ in model membranes and live cells, *Biophys J* 90(11)
1637 (2006) L80-2.
- 1638 [144] J.M. Kwiatek, D.M. Owen, A. Abu-Siniyeh, P. Yan, L.M. Loew, K. Gaus, Characterization
1639 of a new series of fluorescent probes for imaging membrane order, *PLoS One* 8(2) (2013)
1640 e52960.
- 1641 [145] H.M. Kim, H.J. Choo, S.Y. Jung, Y.G. Ko, W.H. Park, S.J. Jeon, C.H. Kim, T. Joo, B.R. Cho,
1642 A two-photon fluorescent probe for lipid raft imaging: C-laurdan, *Chembiochem* 8(5)
1643 (2007) 553-9.
- 1644 [146] M.L. Salinas, N.R. Fuentes, R. Choate, R.C. Wright, D.N. McMurray, R.S. Chapkin,
1645 AdipoRon Attenuates Wnt Signaling by Reducing Cholesterol-Dependent Plasma
1646 Membrane Rigidity, *Biophys J* 118(4) (2020) 885-897.
- 1647 [147] E. Sezgin, Y. Azbazar, X.W. Ng, C. Teh, K. Simons, G. Weidinger, T. Wohland, C.
1648 Eggeling, G. Ozhan, Binding of canonical Wnt ligands to their receptor complexes occurs
1649 in ordered plasma membrane environments, *Febs J* 284(15) (2017) 2513-2526.
- 1650 [148] D.H. KENNETH A. FIELD, BARBARA BAIRD, FcεRI-mediated recruitment of
1651 p53/56'ly to detergent-resistant membrane domains accompanies cellular signaling,
1652 *Proc.Natl.Acad.Sci.USA* (1995).
- 1653 [149] J.L. Thorne, S. Battaglia, D.E. Baxter, J.L. Hayes, S.A. Hutchinson, S. Jana, R.A. Millican-
1654 Slater, L. Smith, M.C. Teske, L.M. Wastall, T.A. Hughes, MiR-19b non-canonical binding is
1655 directed by HuR and confers chemosensitivity through regulation of P-glycoprotein in
1656 breast cancer, *Biochim Biophys Acta Gene Regul Mech* 1861(11) (2018).
- 1657 [150] P.K. Swain, R.J. Verma, J. Bajpai, A.P. Desai, V. Prabhakaran, B.S. Sharma, Post-
1658 translational Modifications (PTMs), from a Cancer Perspective: An Overview, *Oncogen*
1659 2(3) (2019).
- 1660 [151] R.J. Brown DA, Sorting of GPI-Anchored Proteins to Glycolipid-Enriched Membrane
1661 Subdomains during Transport to the Apical Cell Surface, *Cell Press* (1992).
- 1662 [152] E.J. Smart, Y.S. Ying, C. Mineo, R.G. Anderson, A detergent-free method for purifying
1663 caveolae membrane from tissue culture cells, *Proc Natl Acad Sci U S A* 92(22) (1995)
1664 10104-8.
- 1665 [153] M. Menke, S. Kunneke, A. Janshoff, Lateral organization of GM1 in phase-separated
1666 monolayers visualized by scanning force microscopy, *European biophysics journal : EBJ*
1667 31(4) (2002) 317-22.
- 1668 [154] Z. Yang, W. Qin, Y. Chen, B. Yuan, X. Song, B. Wang, F. Shen, J. Fu, H. Wang, Cholesterol
1669 inhibits hepatocellular carcinoma invasion and metastasis by promoting CD44
1670 localization in lipid rafts, *Cancer Lett* 429 (2018) 66-77.
- 1671 [155] F. Perrotti, C. Rosa, I. Cicalini, P. Sacchetta, P. Del Boccio, D. Genovesi, D.
1672 Pieragostino, Advances in Lipidomics for Cancer Biomarkers Discovery, *Int J Mol Sci*
1673 17(12) (2016).
- 1674 [156] E. Maciel, J. Felgueiras, E.M.P. Silva, F. Ricardo, A.S.P. Moreira, T. Melo, A. Campos,
1675 M. Fardilha, P. Domingues, M.R. Domingues, Lipid remodelling in human melanoma cells
1676 in response to UVA exposure, *Photochem Photobiol Sci* 16(5) (2017) 744-752.

1677 [157] M.W. He, S. Guo, Z.L. Li, In situ characterizing membrane lipid phenotype of breast
1678 cancer cells using mass spectrometry profiling, *Sci Rep-Uk* 5 (2015).

1679 [158] A. Buck, A. Ly, B. Balluff, N. Sun, K. Gorzolka, A. Feuchtinger, K.P. Janssen, P.J. Kuppen,
1680 C.J. van de Velde, G. Weirich, F. Erlmeier, R. Langer, M. Aubele, H. Zitzelsberger, M. Aichler,
1681 A. Walch, High-resolution MALDI-FT-ICR MS imaging for the analysis of metabolites from
1682 formalin-fixed, paraffin-embedded clinical tissue samples, *J Pathol* 237(1) (2015) 123-32.

1683 [159] J.F. Frisz, K. Lou, H.A. Klitzing, W.P. Hanafin, V. Lizunov, R.L. Wilson, K.J. Carpenter,
1684 R. Kim, I.D. Hutcheon, J. Zimmerberg, P.K. Weber, M.L. Kraft, Direct chemical evidence for
1685 sphingolipid domains in the plasma membranes of fibroblasts, *Proc Natl Acad Sci U S A*
1686 110(8) (2013) E613-22.

1687 [160] S.J. Marrink, V. Corradi, P.C.T. Souza, H.I. Ingolfsson, D.P. Tieleman, M.S.P. Sansom,
1688 Computational Modeling of Realistic Cell Membranes, *Chem Rev* (2019).

1689 [161] V. Corradi, B.I. Sejdiu, H. Mesa-Galloso, H. Abdizadeh, S.Y. Noskov, S.J. Marrink, D.P.
1690 Tieleman, Emerging Diversity in Lipid-Protein Interactions, *Chem Rev* 119(9) (2019)
1691 5775-5848.

1692 [162] S.J. Marrink, H.J. Risselada, S. Yefimov, D.P. Tieleman, A.H. de Vries, The MARTINI
1693 force field: coarse grained model for biomolecular simulations, *J Phys Chem B* 111(27)
1694 (2007) 7812-24.

1695 [163] H.I. Ingolfsson, M.N. Melo, F.J. van Eerden, C. Arnarez, C.A. Lopez, T.A. Wassenaar, X.
1696 Periole, A.H. de Vries, D.P. Tieleman, S.J. Marrink, Lipid organization of the plasma
1697 membrane, *J Am Chem Soc* 136(41) (2014) 14554-9.

1698 [164] H.I. Ingolfsson, T.S. Carpenter, H. Bhatia, P.T. Bremer, S.J. Marrink, F.C. Lightstone,
1699 Computational Lipidomics of the Neuronal Plasma Membrane, *Biophys J* 113(10) (2017)
1700 2271-2280.

1701 [165] Y. Andoh, S. Okazaki, R. Ueoka, Molecular dynamics study of lipid bilayers modeling
1702 the plasma membranes of normal murine thymocytes and leukemic GRSL cells, *Bba-*
1703 *Biomembranes* 1828(4) (2013) 1259-1270.

1704 [166] H. Koldso, D. Shorthouse, J. Helie, M.S. Sansom, Lipid clustering correlates with
1705 membrane curvature as revealed by molecular simulations of complex lipid bilayers, *PLoS*
1706 *computational biology* 10(10) (2014) e1003911.

1707 [167] D.H. de Jong, C.A. Lopez, S.J. Marrink, Molecular view on protein sorting into liquid-
1708 ordered membrane domains mediated by gangliosides and lipid anchors, *Faraday*
1709 *Discuss.* 161 (2013) 347-363.

1710 [168] A.J. Sodt, M.L. Sandar, K. Gawrisch, R.W. Pastor, E. Lyman, The molecular structure
1711 of the liquid-ordered phase of lipid bilayers, *J Am Chem Soc* 136(2) (2014) 725-32.

1712 [169] J.D. Perlmutter, J.N. Sachs, Inhibiting Lateral Domain Formation in Lipid Bilayers:
1713 Simulations of Alternative Steroid Headgroup Chemistries, (2009).

1714 [170] G. Moiset, C.A. Lopez, R. Bartelds, L. Syga, E. Rijpkema, A. Cukkemane, M. Baldus, B.
1715 Poolman, S.J. Marrink, Disaccharides impact the lateral organization of lipid membranes,
1716 *J Am Chem Soc* 136(46) (2014) 16167-75.

1717 [171] C. Rosetti, C. Pastorino, Polyunsaturated and saturated phospholipids in mixed
1718 bilayers: a study from the molecular scale to the lateral lipid organization, *J Phys Chem B*
1719 115(5) (2011) 1002-13.

1720 [172] X. Lin, J.H. Lorent, A.D. Skinkle, K.R. Levental, M.N. Waxham, A.A. Gorfe, I. Levental,
1721 Domain Stability in Biomimetic Membranes Driven by Lipid Polyunsaturation, *J Phys*
1722 *Chem B* 120(46) (2016) 11930-11941.

- 1723 [173] S. Thallmair, H.I. Ingolfsson, S.J. Marrink, Cholesterol Flip-Flop Impacts Domain
1724 Registration in Plasma Membrane Models, *J Phys Chem Lett* 9(18) (2018) 5527-5533.
- 1725 [174] D.W. Russell, Oxysterol biosynthetic enzymes, *Biochimica et Biophysica Acta*
1726 (2000).
- 1727 [175] W. Kulig, H. Mikkolainen, A. Olzynska, P. Jurkiewicz, L. Cwiklik, M. Hof, I. Vattulainen,
1728 P. Jungwirth, T. Rog, Bobbing of Oxysterols: Molecular Mechanism for Translocation of
1729 Tail-Oxidized Sterols through Biological Membranes, *J Phys Chem Lett* 9(5) (2018) 1118-
1730 1123.
- 1731 [176] G. Hedger, M.S. Sansom, H. Koldso, The juxtamembrane regions of human receptor
1732 tyrosine kinases exhibit conserved interaction sites with anionic lipids, *Sci Rep* 5 (2015)
1733 9198.
- 1734 [177] H. Koldso, M.S. Sansom, Organization and Dynamics of Receptor Proteins in a
1735 Plasma Membrane, *J Am Chem Soc* 137(46) (2015) 14694-704.
- 1736 [178] M. Chavent, A.P. Chetwynd, P.J. Stansfeld, M.S. Sansom, Dimerization of the EphA1
1737 receptor tyrosine kinase transmembrane domain: Insights into the mechanism of
1738 receptor activation, *Biochemistry* 53(42) (2014) 6641-52.
- 1739 [179] M. Chavent, D. Karia, A.C. Kalli, J. Domanski, A.L. Duncan, G. Hedger, P.J. Stansfeld, E.
1740 Seiradake, E.Y. Jones, M.S.P. Sansom, Interactions of the EphA2 Kinase Domain with PIPs
1741 in Membranes: Implications for Receptor Function, *Structure* 26(7) (2018) 1025-1034
1742 e2.
- 1743 [180] A.B. Pawar, D. Sengupta, Effect of Membrane Composition on Receptor Association:
1744 Implications of Cancer Lipidomics on ErbB Receptors, *The Journal of membrane biology*
1745 251(3) (2018) 359-368.
- 1746 [181] X. Prasanna, P.J. Praveen, D. Sengupta, Sequence dependent lipid-mediated effects
1747 modulate the dimerization of ErbB2 and its associative mutants, *Phys Chem Chem Phys*
1748 15(43) (2013) 19031-19041.
- 1749 [182] A. Prakash, L. Janosi, M. Doxastakis, Self-Association of Models of Transmembrane
1750 Domains of ErbB Receptors in a Lipid Bilayer, *Biophysical Journal* 99(11) (2010) 3657-
1751 3665.
- 1752 [183] A. Prakash, L. Janosi, M. Doxastakis, GxxxG Motifs, Phenylalanine, and Cholesterol
1753 Guide the Self-Association of Transmembrane Domains of ErbB2 Receptors, *Biophysical*
1754 *Journal* 101(8) (2011) 1949-1958.
- 1755 [184] N. Bag, S.R. Huang, T. Wohland, Plasma Membrane Organization of Epidermal
1756 Growth Factor Receptor in Resting and Ligand-Bound States, *Biophysical Journal* 109(9)
1757 (2015) 1925-1936.
- 1758 [185] K.B. Abd Halim, H. Koldso, M.S.P. Sansom, Interactions of the EGFR juxtamembrane
1759 domain with PIP2-containing lipid bilayers: Insights from multiscale molecular dynamics
1760 simulations, *Biochim Biophys Acta* 1850(5) (2015) 1017-1025.
- 1761 [186] I.E. Michailidis, R. Rusinova, A. Georgakopoulos, Y. Chen, R. Iyengar, N.K. Robakis,
1762 D.E. Logothetis, L. Baki, Phosphatidylinositol-4,5-bisphosphate regulates epidermal
1763 growth factor receptor activation, *Pflügers Arch* 461(3) (2011) 387-97.
- 1764 [187] Arkhipov A., Shan Y., Das R., Endres F., Estwood M.P., Wemmer D.E., Kuriyan J., S.
1765 D.E., Architecture and membrane interactions of the EGF receptor, (2013).
- 1766 [188] K. Kaszuba, M. Grzybek, A. Orłowski, R. Danne, T. Rog, K. Simons, U. Coskun, I.
1767 Vattulainen, N-Glycosylation as determinant of epidermal growth factor receptor
1768 conformation in membranes, *Proc Natl Acad Sci U S A* 112(14) (2015) 4334-9.

1769 [189] A. Arkhipov, Y. Shan, E.T. Kim, D.E. Shaw, Membrane interaction of bound ligands
1770 contributes to the negative binding cooperativity of the EGF receptor, *PLoS computational*
1771 *biology* 10(7) (2014) e1003742.

1772 [190] T. Reddy, S. Manrique, A. Buyan, B.A. Hall, A. Chetwynd, M.S. Sansom, Primary and
1773 secondary dimer interfaces of the fibroblast growth factor receptor 3 transmembrane
1774 domain: characterization via multiscale molecular dynamics simulations, *Biochemistry*
1775 53(2) (2014) 323-32.

1776 [191] J.S. Desgrosellier, D.A. Cheresh, Integrins in cancer: biological implications and
1777 therapeutic opportunities, *Nature reviews. Cancer* 10(1) (2010) 9-22.

1778 [192] M.H. Ginsberg, A. Partridge, S.J. Shattil, Integrin regulation, *Curr Opin Cell Biol* 17(5)
1779 (2005) 509-16.

1780 [193] A.C. Kalli, T. Rog, I. Vattulainen, I.D. Campbell, M.S.P. Sansom, The Integrin Receptor
1781 in Biologically Relevant Bilayers: Insights from Molecular Dynamics Simulations, *The*
1782 *Journal of membrane biology* 250(4) (2017) 337-351.

1783 [194] A. Orłowski, S. Kukkurainen, A. Poyry, S. Rissanen, I. Vattulainen, V.P. Hytonen, T.
1784 Rog, PIP2 and Talin Join Forces to Activate Integrin, *Journal of Physical Chemistry B*
1785 119(38) (2015) 12381-12389.

1786 [195] D. Provasi, A. Negri, B.S. Coller, M. Filizola, Talin-driven inside-out activation
1787 mechanism of platelet alphaIIb beta3 integrin probed by multimicrosecond, all-atom
1788 molecular dynamics simulations, *Proteins* 82(12) (2014) 3231-3240.

1789 [196] J. Guo, Y. Zhang, H. Li, H. Chu, Q. Wang, S. Jiang, Y. Li, H. Shen, G. Li, J. Chen, C. Xu,
1790 Intramembrane ionic protein-lipid interaction regulates integrin structure and function,
1791 *PLoS Biol* 16(11) (2018) e2006525.

1792 [197] W. Cho, R.V. Stahelin, Membrane-protein interactions in cell signaling and
1793 membrane trafficking, *Annual review of biophysics and biomolecular structure* 34 (2005)
1794 119-51.

1795 [198] E. Yamamoto, A.C. Kalli, T. Akimoto, K. Yasuoka, M.S. Sansom, Anomalous Dynamics
1796 of a Lipid Recognition Protein on a Membrane Surface, *Sci Rep* 5 (2015) 18245.

1797 [199] E. Yamamoto, A.C. Kalli, K. Yasuoka, M.S.P. Sansom, Interactions of Pleckstrin
1798 Homology Domains with Membranes: Adding Back the Bilayer via High-Throughput
1799 Molecular Dynamics, *Structure* 24(8) (2016) 1421-1431.

1800 [200] A. Buyan, A.C. Kalli, M.S.P. Sansom, Multiscale Simulations Suggest a Mechanism for
1801 the Association of the Dok7 PH Domain with PIP-Containing Membranes, *PLoS*
1802 *computational biology* 12(7) (2016).

1803 [201] A.T. Yamamoto E, Kalli AC, Yasuoka K, Sansom MSP, Dynamic interactions between
1804 a membrane binding protein and lipids induce fluctuating diffusivity, *SCIENCE*
1805 *ADVANCES-Biophysics* (2017).

1806 [202] J. Zhou, C. Aponte-Santamaria, S. Sturm, J.T. Bullerjahn, A. Bronowska, F. Grater,
1807 Mechanism of Focal Adhesion Kinase Mechanosensing, *PLoS computational biology*
1808 11(11) (2015) e1004593.

1809 [203] P. Prakash, Y. Zhou, H. Liang, J.F. Hancock, A.A. Gorfe, Oncogenic K-Ras Binds to an
1810 Anionic Membrane in Two Distinct Orientations: A Molecular Dynamics Analysis, *Biophys*
1811 *J* 110(5) (2016) 1125-38.

1812 [204] L. Janosi, Z. Li, J.F. Hancock, A.A. Gorfe, Organization, dynamics, and segregation of
1813 Ras nanoclusters in membrane domains, *Proc Natl Acad Sci U S A* 109(21) (2012) 8097-
1814 102.

1815 [205] Z. Li, L. Janosi, A.A. Gorfe, Formation and domain partitioning of H-ras peptide
1816 nanoclusters: effects of peptide concentration and lipid composition, *J Am Chem Soc*
1817 134(41) (2012) 17278-85.

1818 [206] E. Jefferys, M.S.P. Sansom, P.W. Fowler, NRas slows the rate at which a model lipid
1819 bilayer phase separates, *Faraday Discuss* 169 (2014) 209-223.

1820 [207] H. Li, A.A. Gorfe, Aggregation of lipid-anchored full-length H-Ras in lipid bilayers:
1821 simulations with the MARTINI force field, *PLoS One* 8(7) (2013) e71018.

1822 [208] M.J. Arcario, E. Tajkhorshid, Membrane-induced structural rearrangement and
1823 identification of a novel membrane anchor in talin F2F3, *Biophys J* 107(9) (2014) 2059-
1824 69.

1825 [209] A.C. Kalli, I.D. Campbell, M.S. Sansom, Conformational changes in talin on binding to
1826 anionic phospholipid membranes facilitate signaling by integrin transmembrane helices,
1827 *PLoS Comput Biol* 9(10) (2013) e1003316.

1828 [210] A.C. Kalli, I. Devaney, M.S. Sansom, Interactions of phosphatase and tensin
1829 homologue (PTEN) proteins with phosphatidylinositol phosphates: insights from
1830 molecular dynamics simulations of PTEN and voltage sensitive phosphatase,
1831 *Biochemistry* 53(11) (2014) 1724-32.

1832 [211] F.B. Naughton, A.C. Kalli, M.S. Sansom, Association of Peripheral Membrane Proteins
1833 with Membranes: Free Energy of Binding of GRP1 PH Domain with Phosphatidylinositol
1834 Phosphate-Containing Model Bilayers, *J Phys Chem Lett* 7(7) (2016) 1219-24.

1835 [212] G. Hedger, D. Shorthouse, H. Koldso, M.S. Sansom, Free Energy Landscape of Lipid
1836 Interactions with Regulatory Binding Sites on the Transmembrane Domain of the EGF
1837 Receptor, *J Phys Chem B* 120(33) (2016) 8154-63.

1838 [213] K.C. Chan, L. Lu, F. Sun, J. Fan, Molecular Details of the PH Domain of ACAP1(BAR-
1839 PH) Protein Binding to PIP-Containing Membrane, *J Phys Chem B* 121(15) (2017) 3586-
1840 3596.

1841 [214] F.B. Naughton, A.C. Kalli, M.S.P. Sansom, Modes of Interaction of Pleckstrin
1842 Homology Domains with Membranes: Toward a Computational Biochemistry of
1843 Membrane Recognition, *Journal of molecular biology* 430(3) (2018) 372-388.

1844 [215] D. Lu, J. Jiang, Z. Liang, M. Sun, C. Luo, B. Shen, G. Hu, Molecular dynamic simulation
1845 to explore the molecular basis of Btk-PH domain interaction with Ins(1,3,4,5)P4,
1846 *TheScientificWorldJournal* 2013 (2013) 580456.

1847 [216] S.A. Rosen, P.R. Gaffney, B. Spiess, I.R. Gould, Understanding the relative affinity and
1848 specificity of the pleckstrin homology domain of protein kinase B for inositol phosphates,
1849 *Phys Chem Chem Phys* 14(2) (2012) 929-36.

1850 [217] A.J. García-Sáez, P. Schwille, Single molecule techniques for the study of membrane
1851 proteins, *Applied microbiology and biotechnology* 76(2) (2007) 257-266.

1852 [218] A.A. Deniz, S. Mukhopadhyay, E.A. Lemke, Single-molecule biophysics: at the
1853 interface of biology, physics and chemistry, *J R Soc Interface* 5(18) (2008) 15-45.

1854 [219] I. Tinoco, Jr., R.L. Gonzalez, Jr., Biological mechanisms, one molecule at a time, *Genes*
1855 *Dev* 25(12) (2011) 1205-31.

1856 [220] A.J. Garcia-Saez, P. Schwille, Single molecule techniques for the study of membrane
1857 proteins, *Appl Microbiol Biotechnol* 76(2) (2007) 257-66.

1858 [221] E. Hermann, J. Ries, A.J. Garcia-Saez, Scanning fluorescence correlation
1859 spectroscopy on biomembranes, *Methods in molecular biology* 1232 (2015) 181-97.

1860 [222] D.R. Larson, Y.M. Ma, V.M. Vogt, W.W. Webb, Direct measurement of Gag-Gag
1861 interaction during retrovirus assembly with FRET and fluorescence correlation
1862 spectroscopy, *J Cell Biol* 162(7) (2003) 1233-44.

1863 [223] R. Lasserre, X.J. Guo, F. Conchonaud, Y. Hamon, O. Hawchar, A.M. Bernard, S.M.
1864 Soudja, P.F. Lenne, H. Rigneault, D. Olive, G. Bismuth, J.A. Nunes, B. Payraastre, D. Marguet,
1865 H.T. He, Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and
1866 activation, *Nat Chem Biol* 4(9) (2008) 538-47.

1867 [224] M. Gerken, A. Krippner-Heidenreich, S. Steinert, S. Willi, F. Neugart, A. Zappe, J.
1868 Wrachtrup, C. Tietz, P. Scheurich, Fluorescence correlation spectroscopy reveals
1869 topological segregation of the two tumor necrosis factor membrane receptors, *Biochim*
1870 *Biophys Acta* 1798(6) (2010) 1081-9.

1871 [225] S.A. Kim, K.G. Heinze, P. Schwille, Fluorescence correlation spectroscopy in living
1872 cells, *Nat Methods* 4(11) (2007) 963-73.

1873 [226] A.D. Douglass, R.D. Vale, Single-molecule microscopy reveals plasma membrane
1874 microdomains created by protein-protein networks that exclude or trap signaling
1875 molecules in T cells, *Cell* 121(6) (2005) 937-50.

1876 [227] J.I. Yuji Teramura, Hiroaki, Takagi, Kenji Nishida, Toshio Yanagida and Yasushi Sako,
1877 Single-molecule analysis of epidermal growth factor binding on the surface of living cells,
1878 *The EMBO Journal* (2006).

1879 [228] S.Y. Nishimura, M. Vrljic, L.O. Klein, H.M. McConnell, W.E. Moerner, Cholesterol
1880 depletion induces solid-like regions in the plasma membrane, *Biophys J* 90(3) (2006)
1881 927-38.

1882 [229] B.E.S.-J. Piet H. M. Lommerse, Herman P. Spaank and Thomas Schmidt, Single-
1883 molecule diffusion measurements of H-Ras at the plasma membrane of live cells reveal
1884 microdomain localization upon activation, *Journal of Cell Science* (2005).

1885 [230] X. Gao, P.R. Lowry, X. Zhou, C. Depry, Z. Wei, G.W. Wong, J. Zhang, PI3K/Akt signaling
1886 requires spatial compartmentalization in plasma membrane microdomains, *Proc Natl*
1887 *Acad Sci U S A* 108(35) (2011) 14509-14.

1888 [231] E.L. Elson, E. Fried, J.E. Dolbow, G.M. Genin, Phase separation in biological
1889 membranes: integration of theory and experiment, *Annu Rev Biophys* 39 (2010) 207-26.

1890 [232] J.R. Lakowicz, Principles of fluorescence spectroscopy, *Analytical Chemistry*
1891 (1999).

1892 [233] S. Saini, H. Singh, B. Bagchi, Fluorescence resonance energy transfer (FRET) in
1893 chemistry and biology: Non-Förster distance dependence of the FRET rate, *J Chem Sci*
1894 118, 23–35 (2006).

1895 [234] X. Gao, J. Zhang, Spatiotemporal analysis of differential Akt regulation in plasma
1896 membrane microdomains, *Mol Biol Cell* 19(10) (2008) 4366-73.

1897 [235] B.B. Tsien RY, Adams SR, FRET for studying intracellular signalling, *Trends Cell Biol*
1898 (1993).

1899 [236] A.R. Burns, D.J. Frankel, T. Buranda, Local mobility in lipid domains of supported
1900 bilayers characterized by atomic force microscopy and fluorescence correlation
1901 spectroscopy, *Biophys J* 89(2) (2005) 1081-93.

1902 [237] M. Parri, P. Chiarugi, Rac and Rho GTPases in cancer cell motility control, *Cell*
1903 *Commun Signal* 8 (2010) 23.

- 1904 [238] H. Murakoshi, R. Iino, T. Kobayashi, T. Fujiwara, C. Ohshima, A. Yoshimura, A.
1905 Kusumi, Single-molecule imaging analysis of Ras activation in living cells, *Proc Natl Acad*
1906 *Sci U S A* 101(19) (2004) 7317-22.
- 1907 [239] S. Chiantia, J. Ries, N. Kahya, P. Schwille, Combined AFM and two-focus SFCS study
1908 of raft-exhibiting model membranes, *Chemphyschem* 7(11) (2006) 2409-18.
- 1909 [240] E. Sezgin, P. Schwille, Fluorescence techniques to study lipid dynamics, *Cold Spring*
1910 *Harb Perspect Biol* 3(11) (2011) a009803.
- 1911 [241] M. Isshiki, Y.S. Ying, T. Fujita, R.G. Anderson, A molecular sensor detects signal
1912 transduction from caveolae in living cells, *J Biol Chem* 277(45) (2002) 43389-98.
- 1913 [242] A.Y. Ting, K.H. Kain, R.L. Klemke, R.Y. Tsien, Genetically encoded fluorescent
1914 reporters of protein tyrosine kinase activities in living cells, *Proc Natl Acad Sci U S A*
1915 98(26) (2001) 15003-8.
- 1916 [243] Z. Mi, H. Guo, M.B. Russell, Y. Liu, B.A. Sullenger, P.C. Kuo, RNA aptamer blockade of
1917 osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells, *Mol Ther*
1918 17(1) (2009) 153-61.
- 1919 [244] V.R. Sharma P, Sarasij RC, Ira, Gousset K, Krishnammorthy G, Rao M, Mayor S, ,
1920 Nanoscale organization of multiple GPI-anchored proteins in living cell membranes, *Cell*
1921 (2004).
- 1922 [245] A. Miyawaki, <Visualization of the Spatial Review.pdf>, (2003).
- 1923 [246] A.S. Klymchenko, Solvatochromic and Fluorogenic Dyes as Environment-Sensitive
1924 Probes: Design and Biological Applications, *Acc Chem Res* 50(2) (2017) 366-375.
- 1925 [247] P.P. Provenzano, K.W. Eliceiri, P.J. Keely, Multiphoton microscopy and fluorescence
1926 lifetime imaging microscopy (FLIM) to monitor metastasis and the tumor
1927 microenvironment, *Clin Exp Metastasis* 26(4) (2009) 357-70.
- 1928 [248] M.A. Moore, The role of chemoattraction in cancer metastases, *BioEssays : news and*
1929 *reviews in molecular, cellular and developmental biology* 23(8) (2001) 674-6.
- 1930 [249] M. Peter, S.M. Ameer-Beg, M.K. Hughes, M.D. Keppler, S. Prag, M. Marsh, B. Vojnovic,
1931 T. Ng, Multiphoton-FLIM quantification of the EGFP-mRFP1 FRET pair for localization of
1932 membrane receptor-kinase interactions, *Biophys J* 88(2) (2005) 1224-37.
- 1933 [250] T. Ahmed, K. Shea, J.R. Masters, G.E. Jones, C.M. Wells, A PAK4-LIMK1 pathway
1934 drives prostate cancer cell migration downstream of HGF, *Cell Signal* 20(7) (2008) 1320-
1935 8.
- 1936 [251] S.D. Connell, D.A. Smith, The atomic force microscope as a tool for studying phase
1937 separation in lipid membranes, *Mol Membr Biol* 23(1) (2006) 17-28.
- 1938 [252] S.D. Connell, G.R. Heath, J.A. Goodchild, Quantitative Analysis of Structure and
1939 Dynamics in AFM Images of Lipid Membranes, *Methods in molecular biology* 1886 (2019)
1940 29-44.
- 1941 [253] M.C. Giocondi, V. Vie, E. Lesniewska, J.P. Goudonnet, C. Le Grimellec, In situ imaging
1942 of detergent-resistant membranes by atomic force microscopy, *Journal of structural*
1943 *biology* 131(1) (2000) 38-43.
- 1944 [254] C.Y.a.L.J. Johnston, Distribution of Ganglioside GM1 in L-a-
1945 Dipalmitoylphosphatidylcholine Cholesterol Monolayers: A Model for Lipid Rafts,
1946 *Biophys J* (2000).
- 1947 [255] C.Y.a.L.J. Johnston, Atomic Force Microscopy Studies of Ganglioside GM1 Domains
1948 in Phosphatidylcholine and Phosphatidylcholine/Cholesterol Bilayers, *biophys J* (2001).

- 1949 [256] S. Chiantia, N. Kahya, J. Ries, P. Schwille, Effects of ceramide on liquid-ordered
1950 domains investigated by simultaneous AFM and FCS, *Biophys J* 90(12) (2006) 4500-8.
- 1951 [257] F. Orsini, A. Cremona, P. Arosio, P.A. Corsetto, G. Montorfano, A. Lascialfari, A.M.
1952 Rizzo, Atomic force microscopy imaging of lipid rafts of human breast cancer cells,
1953 *Biochim Biophys Acta* 1818(12) (2012) 2943-9.
- 1954 [258] P. Pathak, E. London, Measurement of lipid nanodomain (raft) formation and size
1955 in sphingomyelin/POPC/cholesterol vesicles shows TX-100 and transmembrane helices
1956 increase domain size by coalescing preexisting nanodomains but do not induce domain
1957 formation, *Biophys J* 101(10) (2011) 2417-25.
- 1958 [259] C. Lamprecht, M. Gehrman, J. Madl, W. Romer, G. Multhoff, A. Ebner, Molecular AFM
1959 imaging of Hsp70-1A association with dipalmitoyl phosphatidylserine reveals membrane
1960 blebbing in the presence of cholesterol, *Cell stress & chaperones* 23(4) (2018) 673-683.
- 1961 [260] C. Wodlej, S. Riedl, B. Rinner, R. Leber, C. Drechsler, D.R. Voelker, J.Y. Choi, K. Lohner,
1962 D. Zweytick, Interaction of two antitumor peptides with membrane lipids - Influence of
1963 phosphatidylserine and cholesterol on specificity for melanoma cells, *PLoS One* 14(1)
1964 (2019) e0211187.
- 1965 [261] G. Armijo, J. Okerblom, D.M. Cauvi, V. Lopez, D.E. Schlamadinger, J. Kim, N. Arispe, A.
1966 De Maio, Interaction of heat shock protein 70 with membranes depends on the lipid
1967 environment, *Cell stress & chaperones* 19(6) (2014) 877-86.
- 1968 [262] A.X. Cartagena-Rivera, W.H. Wang, R.L. Geahlen, A. Raman, Fast, multi-frequency,
1969 and quantitative nanomechanical mapping of live cells using the atomic force microscope,
1970 *Sci Rep* 5 (2015) 11692.
- 1971 [263] D.S. Alvares, J. Ruggiero Neto, E.E. Ambroggio, Phosphatidylserine lipids and
1972 membrane order precisely regulate the activity of Polybia-MP1 peptide, *Biochim Biophys*
1973 *Acta Biomembr* 1859(6) (2017) 1067-1074.
- 1974 [264] M. Quintela, D.H. Sieglaff, A.S. Gazze, A. Zhang, D. Gonzalez, L. Francis, P. Webb, R.S.
1975 Conlan, HBO1 directs histone H4 specific acetylation, potentiating mechano-transduction
1976 pathways and membrane elasticity in ovarian cancer cells, *Nanomedicine* 17 (2019) 254-
1977 265.
- 1978 [265] M.A. McLean, A.G. Stephen, S.G. Sligar, PIP2 Influences the Conformational
1979 Dynamics of Membrane-Bound KRAS4b, *Biochemistry* 58(33) (2019) 3537-3545.
- 1980 [266] D. Heilos, C. Rohrl, C. Pirker, B. Englinger, D. Baier, T. Mohr, M. Schwaiger, S.M. Iqbal,
1981 S. van Schoonhoven, K. Klavins, T. Eberhart, U. Windberger, J. Taibon, S. Sturm, H.
1982 Stuppner, G. Koellensperger, R. Dornetshuber-Fleiss, W. Jager, R. Lemmens-Gruber, W.
1983 Berger, Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives
1984 cancer cell resistance to destruxins, *Oncotarget* 9(39) (2018) 25661-25680.
- 1985 [267] A. Sakai, A.P. de Sousa Mesquita, E.V. de Castro Levatti, A.H. Straus, H.B. Nader, C.C.
1986 Lopes, L. Caseli, Interaction of Trastuzumab with biomembrane models at air-water
1987 interfaces mimicking cancer cell surfaces, *Biochim Biophys Acta Biomembr* 1861(10)
1988 (2019) 182992.
- 1989 [268] X. Deng, F. Xiong, X. Li, B. Xiang, Z. Li, X. Wu, C. Guo, X. Li, Y. Li, G. Li, W. Xiong, Z. Zeng,
1990 Application of atomic force microscopy in cancer research, *J Nanobiotechnology* 16(1)
1991 (2018) 102.
- 1992 [269] C.P. Toseland, Fluorescent labeling and modification of proteins, *J Chem Biol* 6(3)
1993 (2013) 85-95.

- 1994 [270] W. Wang, Y. Yang, S. Wang, V.J. Nagaraj, Q. Liu, J. Wu, N. Tao, Label-free measuring
1995 and mapping of binding kinetics of membrane proteins in single living cells, *Nature*
1996 *chemistry* 4(10) (2012) 846-53.
- 1997 [271] E.T. Roussos, J.S. Condeelis, A. Patsialou, Chemotaxis in cancer, *Nature reviews.*
1998 *Cancer* 11(8) (2011) 573-87.
- 1999 [272] A.I. Tyler, R.V. Law, J.M. Seddon, X-ray diffraction of lipid model membranes,
2000 *Methods in molecular biology* 1232 (2015) 199-225.
- 2001 [273] P.J. Quinn, C. Wolf, An X-ray diffraction study of model membrane raft structures,
2002 *Febs J* 277(22) (2010) 4685-4698.
- 2003 [274] D. Marquardt, F.A. Heberle, J.D. Nickels, G. Pabst, J. Katsaras, On scattered waves and
2004 lipid domains: detecting membrane rafts with X-rays and neutrons, *Soft Matter* 11(47)
2005 (2015) 9055-9072.
- 2006 [275] K.Y. Levine, X-Ray Diffraction Studies of Membranes, *Progress in Surface Science*
2007 (1973).
- 2008 [276] T.J. McIntosh, The effect of cholesterol on the structure of phosphatidylcholine
2009 bilayers, *Biochim Biophys Acta* 513(1) (1978) 43-58.
- 2010 [277] M. Sega, G. Garberoglio, P. Brocca, L. Cantu, Microscopic structure of phospholipid
2011 bilayers: Comparison between molecular dynamics simulations and wide-angle X-ray
2012 spectra, *Journal of Physical Chemistry B* 111(10) (2007) 2484-2489.
- 2013 [278] D.M. Freed, D. Alvarado, M.A. Lemmon, Ligand regulation of a constitutively dimeric
2014 EGF receptor, *Nature communications* 6 (2015) 7380.
- 2015 [279] A. Hodzic, M. Rappolt, H. Amenitsch, P. Laggner, G. Pabst, Differential modulation of
2016 membrane structure and fluctuations by plant sterols and cholesterol, *Biophys J* 94(10)
2017 (2008) 3935-44.
- 2018 [280] I.A. Prior, A. Harding, J. Yan, J. Sluimer, R.G. Parton, J.F. Hancock, GTP-dependent
2019 segregation of H-ras from lipid rafts is required for biological activity, *Nat Cell Biol* 3(4)
2020 (2001) 368-75.
- 2021 [281] I.A. Prior, C. Muncke, R.G. Parton, J.F. Hancock, Direct visualization of Ras proteins
2022 in spatially distinct cell surface microdomains, *J Cell Biol* 160(2) (2003) 165-70.
- 2023 [282] V. Zarembeg, S. Ganesan, M. Mahadeo, Lipids and Membrane Microdomains: The
2024 Glycerolipid and Alkylphosphocholine Class of Cancer Chemotherapeutic Drugs, *Handb*
2025 *Exp Pharmacol* 259 (2020) 261-288.
- 2026 [283] T. Koltai, Nelfinavir and other protease inhibitors in cancer: mechanisms involved
2027 in anticancer activity, *F1000Res* 4 (2015) 9.
- 2028 [284] O. Belzile, X. Huang, J. Gong, J. Carlson, A.J. Schroit, R.A. Brekken, B.D. Freemark,
2029 Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer,
2030 *Immunotargets Ther* 7 (2018) 1-14.
- 2031 [285] M. Lekka, P. Laidler, Applicability of AFM in cancer detection, *Nat Nanotechnol* 4(2)
2032 (2009) 72; author reply 72-3.
- 2033 [286] Z. Lu, Z. Wang, D. Li, Application of atomic force microscope in diagnosis of single
2034 cancer cells, *Biomicrofluidics* 14(5) (2020) 051501.
- 2035 [287] A. Stylianou, M. Lekka, T. Stylianopoulos, AFM assessing of nanomechanical
2036 fingerprints for cancer early diagnosis and classification: from single cell to tissue level,
2037 *Nanoscale* 10(45) (2018) 20930-20945.

2038 [288] P. Deptula, D. Lysik, K. Pogoda, M. Ciesluk, A. Namiot, J. Mystkowska, G. Krol, S.
2039 Gluszek, P.A. Janmey, R. Bucki, Tissue Rheology as a Possible Complementary Procedure
2040 to Advance Histological Diagnosis of Colon Cancer, ACS Biomater Sci Eng 6(10) (2020)
2041 5620-5631.
2042